Nelfinavir

Identification

Name

Nelfinavir

Accession Number

DB00220  (APRD00003)

Type

Small Molecule

Groups

Approved

Description

Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles.

Structure

3D

Download

MOLSDF3D-SDFPDBSMILESInChI

Similar Structures

Structure for DB00220 (Nelfinavir)

×

Close

Synonyms

Not Available

External IDs

AG1343

Product Ingredients

Ingredient	UNII	CAS	InChI Key
Nelfinavir mesylate	98D603VP8V	159989-65-8	NQHXCOAXSHGTIA-SKXNDZRYSA-N

Product Images

Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Viracept	Tablet, film coated	625 mg/1	Oral	Remedy Repack	2013-03-27	2016-03-11
Viracept	Tablet, film coated	625 mg/1	Oral	Agouron Pharmaceuticals	2003-04-30	Not applicable
Viracept	Tablet	625 mg	Oral	Pfizer	2004-08-11	Not applicable
Viracept	Tablet, film coated	625 mg/1	Oral	State of Florida DOH Central Pharmacy	2009-07-01	Not applicable
Viracept	Tablet, film coated	250 mg/1	Oral	Agouron Pharmaceuticals	1997-03-14	Not applicable
Viracept	Tablet, film coated	250 mg/1	Oral	H.J. Harkins Company	1997-03-14	Not applicable
Viracept	Tablet, film coated	250 mg/1	Oral	Pd Rx Pharmaceuticals, Inc.	1997-03-14	Not applicable
Viracept	Powder	50 mg/g	Oral	Agouron Pharmaceuticals	1997-03-14	2016-02-26
Viracept -250mg	Tablet	250 mg	Oral	Pfizer	1998-09-21	Not applicable
Viracept -50mg	Powder	50 mg	Oral	Pfizer	1998-09-21	Not applicable

Categories

• Anti-HIV Agents
• Anti-Infective Agents
• Anti-Retroviral Agents
• Antiinfectives for Systemic Use
• Antiviral Agents
• Antivirals for Systemic Use
• BCRP/ABCG2 Inhibitors
• Combined Inhibitors of CYP3A4 and P-glycoprotein (Strong)
• Cytochrome P-450 CYP3A Inhibitors
• Cytochrome P-450 CYP3A Inhibitors (strong)
• Cytochrome P-450 CYP3A Substrates
• Cytochrome P-450 CYP3A4 Inhibitors
• Cytochrome P-450 CYP3A4 Inhibitors (strong)
• Cytochrome P-450 CYP3A4 Substrates
• Cytochrome P-450 CYP3A4 Substrates (strength unknown)
• Cytochrome P-450 CYP3A5 Inhibitors (strong)
• Cytochrome P-450 CYP3A7 Inhibitors (strong)
• Cytochrome P-450 Enzyme Inhibitors
• Direct Acting Antivirals
• Enzyme Inhibitors
• HIV Protease Inhibitors
• Hyperglycemia-Associated Agents
• Isoquinolines
• OATP1B1/SLCO1B1 Inhibitors
• OATP1B3 transporter inhibitors
• P-glycoprotein/ABCB1 Inducers
• P-glycoprotein/ABCB1 Inhibitors
• P-glycoprotein/ABCB1 Substrates
• Potential QTc-Prolonging Agents
• Protease Inhibitors
• QTc Prolonging Agents
• UGT1A1 Inducers

UNII

HO3OGH5D7I

CAS number

159989-64-7

Weight

Average: 567.782
Monoisotopic: 567.313077633

Chemical Formula

C₃₂H₄₅N₃O₄S

InChI Key

QAGYKUNXZHXKMR-HKWSIXNMSA-N

InChI

InChI=1S/C32H45N3O4S/c1-21-25(15-10-16-28(21)36)30(38)33-26(20-40-24-13-6-5-7-14-24)29(37)19-35-18-23-12-9-8-11-22(23)17-27(35)31(39)34-32(2,3)4/h5-7,10,13-16,22-23,26-27,29,36-37H,8-9,11-12,17-20H2,1-4H3,(H,33,38)(H,34,39)/t22-,23+,26-,27-,29+/m0/s1

IUPAC Name

(3S,4aS,8aS)-N-tert-butyl-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylphenyl)formamido]-4-(phenylsulfanyl)butyl]-decahydroisoquinoline-3-carboxamide

SMILES

[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[C@H](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C

Pharmacology

Indication

Used in combination with other antiviral drugs in the treatment of HIV in both adults and children.

Associated Conditions

• Infection, Human Immunodeficiency Virus I

Pharmacodynamics

Nelfinavir is a protease inhibitor with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Protease inhibitors block the part of HIV called protease. HIV-1 protease is an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1. Nelfinavir binds to the protease active site and inhibits the activity of the enzyme. This inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature non-infectious viral particles. Protease inhibitors are almost always used in combination with at least two other anti-HIV drugs.

Mechanism of action

Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles.

Target	Actions	Organism
AHIV-1 protease	inhibitor	Human immunodeficiency virus

Absorption

Well absorbed following oral administration.

Volume of distribution

• 2 to 7 L/kg

Protein binding

>98%

Metabolism

Primarily hepatic via cytochrome P450 (CYP450) enzymes. CYP3A and CYP2C19 appear to be the predominant enzymes that metabolize nelfinavir in humans. One major and several minor metabolites are found in plasma; the major oxidative metabolite has in vitro antiviral activity comparable to that of the parent drug.

• Nelfinavir
  Nelfinavir hydroxyl-t- butylamide
• Nelfinavir
  3,4-Dihydroxynelfinavir

Route of elimination

The terminal half-life in plasma was typically 3.5 to 5 hours. The majority (87%) of an oral 750 mg dose containing 14C-nelfinavir was recovered in the feces; fecal radioactivity consisted of numerous oxidative metabolites (78%) and unchanged nelfinavir (22%). Only 1–2% of the dose was recovered in urine, of which unchanged nelfinavir was the major component.

Half life

3.5 - 5 hours

Clearance

Not Available

Toxicity

Oral LD₅₀ is over 5g/kg in rats. Side effects include thirst and hunger, unexplained weight loss, increased urination, fatigue, and dry, itchy skin.

Affected organisms

• Human Immunodeficiency Virus

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
(1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE	The therapeutic efficacy of (1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE can be decreased when used in combination with Nelfinavir.	Experimental
16-Bromoepiandrosterone	The serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Nelfinavir.	Investigational
19-norandrostenedione	The serum concentration of 19-norandrostenedione can be increased when it is combined with Nelfinavir.	Experimental, Illicit
2,4-thiazolidinedione	The therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Nelfinavir.	Investigational
5-androstenedione	The serum concentration of 5-androstenedione can be increased when it is combined with Nelfinavir.	Experimental, Illicit
Abacavir	The serum concentration of Abacavir can be decreased when it is combined with Nelfinavir.	Approved, Investigational
Abemaciclib	The risk or severity of adverse effects can be increased when Nelfinavir is combined with Abemaciclib.	Approved, Investigational
Abiraterone	The metabolism of Abiraterone can be decreased when combined with Nelfinavir.	Approved
Acarbose	The therapeutic efficacy of Acarbose can be decreased when used in combination with Nelfinavir.	Approved, Investigational
Acenocoumarol	The metabolism of Acenocoumarol can be decreased when combined with Nelfinavir.	Approved, Investigational
Acetaminophen	The serum concentration of Acetaminophen can be decreased when it is combined with Nelfinavir.	Approved
Acetohexamide	The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Nelfinavir.	Approved, Investigational, Withdrawn
Acetyl sulfisoxazole	The metabolism of Nelfinavir can be decreased when combined with Acetyl sulfisoxazole.	Approved, Vet Approved
Adinazolam	The metabolism of Adinazolam can be decreased when combined with Nelfinavir.	Approved
Afatinib	The serum concentration of Afatinib can be decreased when it is combined with Nelfinavir.	Approved
Agmatine	The metabolism of Agmatine can be decreased when combined with Nelfinavir.	Experimental, Investigational
AICA ribonucleotide	The therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Nelfinavir.	Experimental, Investigational
Albendazole	The metabolism of Albendazole can be decreased when combined with Nelfinavir.	Approved, Vet Approved
Alclometasone	The metabolism of Alclometasone can be decreased when combined with Nelfinavir.	Approved
Aldosterone	The serum concentration of Aldosterone can be increased when it is combined with Nelfinavir.	Experimental, Investigational
Alfentanil	The metabolism of Alfentanil can be decreased when combined with Nelfinavir.	Approved, Illicit
Alfuzosin	The serum concentration of Alfuzosin can be increased when it is combined with Nelfinavir.	Approved, Investigational
Aliskiren	The metabolism of Aliskiren can be decreased when combined with Nelfinavir.	Approved, Investigational
Allicin	The therapeutic efficacy of Allicin can be decreased when used in combination with Nelfinavir.	Investigational
Allylestrenol	The metabolism of Allylestrenol can be decreased when combined with Nelfinavir.	Approved
Almotriptan	The serum concentration of Almotriptan can be increased when it is combined with Nelfinavir.	Approved, Investigational
Alogliptin	The metabolism of Alogliptin can be decreased when combined with Nelfinavir.	Approved
Alosetron	The serum concentration of Alosetron can be increased when it is combined with Nelfinavir.	Approved, Withdrawn
alpha-Tocopherol acetate	The metabolism of alpha-Tocopherol acetate can be decreased when combined with Nelfinavir.	Approved
Alprazolam	The serum concentration of Alprazolam can be increased when it is combined with Nelfinavir.	Approved, Illicit, Investigational
Ambrisentan	The metabolism of Ambrisentan can be decreased when combined with Nelfinavir.	Approved, Investigational
Ambroxol	The metabolism of Ambroxol can be decreased when combined with Nelfinavir.	Approved, Investigational
Ambroxol acefyllinate	The serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Nelfinavir.	Experimental, Investigational
Amcinonide	The serum concentration of Amcinonide can be increased when it is combined with Nelfinavir.	Approved
Amineptine	The serum concentration of Amineptine can be increased when it is combined with Nelfinavir.	Illicit, Withdrawn
Aminophenazone	The metabolism of Aminophenazone can be decreased when combined with Nelfinavir.	Approved, Withdrawn
Aminophylline	The metabolism of Aminophylline can be decreased when combined with Nelfinavir.	Approved
Amiodarone	The risk or severity of Cardiac Arrhythmia can be increased when Nelfinavir is combined with Amiodarone.	Approved, Investigational
Amitriptyline	The metabolism of Amitriptyline can be decreased when combined with Nelfinavir.	Approved
Amitriptylinoxide	The serum concentration of Amitriptylinoxide can be increased when it is combined with Nelfinavir.	Approved, Investigational
Amlodipine	The metabolism of Amlodipine can be decreased when combined with Nelfinavir.	Approved
Amoxapine	The serum concentration of Amoxapine can be increased when it is combined with Nelfinavir.	Approved
Amprenavir	The metabolism of Amprenavir can be decreased when combined with Nelfinavir.	Approved, Investigational
Anagrelide	Nelfinavir may increase the QTc-prolonging activities of Anagrelide.	Approved
Androstenedione	The serum concentration of Androstenedione can be increased when it is combined with Nelfinavir.	Experimental, Illicit
Anecortave	The serum concentration of Anecortave can be increased when it is combined with Nelfinavir.	Investigational
anecortave acetate	The serum concentration of anecortave acetate can be increased when it is combined with Nelfinavir.	Investigational
Antipyrine	The metabolism of Antipyrine can be decreased when combined with Nelfinavir.	Approved, Investigational
Apalutamide	The serum concentration of Apalutamide can be increased when it is combined with Nelfinavir.	Approved, Investigational
Apixaban	The serum concentration of Apixaban can be increased when it is combined with Nelfinavir.	Approved
Apremilast	The metabolism of Apremilast can be decreased when combined with Nelfinavir.	Approved, Investigational
Aprepitant	The serum concentration of Nelfinavir can be increased when it is combined with Aprepitant.	Approved, Investigational
Aranidipine	The metabolism of Aranidipine can be decreased when combined with Nelfinavir.	Approved, Investigational
Argatroban	The metabolism of Argatroban can be decreased when combined with Nelfinavir.	Approved, Investigational
Aripiprazole	The serum concentration of Aripiprazole can be increased when it is combined with Nelfinavir.	Approved, Investigational
Armodafinil	The metabolism of Nelfinavir can be decreased when combined with Armodafinil.	Approved, Investigational
Arsenic trioxide	Nelfinavir may increase the QTc-prolonging activities of Arsenic trioxide.	Approved, Investigational
Artemether	The metabolism of Artemether can be decreased when combined with Nelfinavir.	Approved
Asenapine	The serum concentration of Nelfinavir can be decreased when it is combined with Asenapine.	Approved
Astemizole	The serum concentration of Astemizole can be increased when it is combined with Nelfinavir.	Approved, Withdrawn
Asunaprevir	The serum concentration of Asunaprevir can be increased when it is combined with Nelfinavir.	Approved, Investigational, Withdrawn
Atamestane	The serum concentration of Atamestane can be increased when it is combined with Nelfinavir.	Investigational
Atazanavir	The metabolism of Atazanavir can be decreased when combined with Nelfinavir.	Approved, Investigational
Atomoxetine	The metabolism of Nelfinavir can be decreased when combined with Atomoxetine.	Approved
Atorvastatin	The risk or severity of adverse effects can be increased when Nelfinavir is combined with Atorvastatin.	Approved
Avanafil	The serum concentration of Avanafil can be increased when it is combined with Nelfinavir.	Approved
Avatrombopag	The metabolism of Avatrombopag can be decreased when combined with Nelfinavir.	Approved, Investigational
Axitinib	The serum concentration of Axitinib can be increased when it is combined with Nelfinavir.	Approved, Investigational
Azelastine	The metabolism of Azelastine can be decreased when combined with Nelfinavir.	Approved
Azelnidipine	The metabolism of Azelnidipine can be decreased when combined with Nelfinavir.	Approved, Investigational
Azithromycin	The serum concentration of Azithromycin can be increased when it is combined with Nelfinavir.	Approved
Balaglitazone	The therapeutic efficacy of Balaglitazone can be decreased when used in combination with Nelfinavir.	Investigational
Banoxantrone	The metabolism of Banoxantrone can be decreased when combined with Nelfinavir.	Investigational
Baricitinib	The metabolism of Baricitinib can be decreased when combined with Nelfinavir.	Approved, Investigational
Barnidipine	The serum concentration of Barnidipine can be increased when it is combined with Nelfinavir.	Approved
Beclomethasone dipropionate	The metabolism of Beclomethasone dipropionate can be decreased when combined with Nelfinavir.	Approved, Investigational
Bedaquiline	The serum concentration of Bedaquiline can be increased when it is combined with Nelfinavir.	Approved
Bempedoic acid	The therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Nelfinavir.	Investigational
Bencyclane	The metabolism of Bencyclane can be decreased when combined with Nelfinavir.	Experimental
Benidipine	The metabolism of Benidipine can be decreased when combined with Nelfinavir.	Approved, Investigational
Benzatropine	The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Benzatropine.	Approved
Benzphetamine	The metabolism of Benzphetamine can be decreased when combined with Nelfinavir.	Approved, Illicit
Benzyl alcohol	The metabolism of Benzyl alcohol can be decreased when combined with Nelfinavir.	Approved
Bepridil	The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Bepridil.	Approved, Withdrawn
Betamethasone	The serum concentration of Betamethasone can be increased when it is combined with Nelfinavir.	Approved, Vet Approved
Bexarotene	The metabolism of Bexarotene can be decreased when combined with Nelfinavir.	Approved, Investigational
Bezafibrate	The metabolism of Bezafibrate can be decreased when combined with Nelfinavir.	Approved, Investigational
Bicalutamide	The metabolism of Bicalutamide can be decreased when combined with Nelfinavir.	Approved
Bictegravir	The metabolism of Bictegravir can be decreased when combined with Nelfinavir.	Approved, Investigational
Bioallethrin	The metabolism of Bioallethrin can be decreased when combined with Nelfinavir.	Approved, Experimental
Bisoprolol	The metabolism of Bisoprolol can be decreased when combined with Nelfinavir.	Approved
Blonanserin	The metabolism of Blonanserin can be decreased when combined with Nelfinavir.	Approved, Investigational
Boceprevir	The serum concentration of Nelfinavir can be decreased when it is combined with Boceprevir.	Approved, Withdrawn
Bortezomib	The serum concentration of Bortezomib can be increased when it is combined with Nelfinavir.	Approved, Investigational
Bosentan	The serum concentration of Bosentan can be increased when it is combined with Nelfinavir.	Approved, Investigational
Bosutinib	The serum concentration of Bosutinib can be increased when it is combined with Nelfinavir.	Approved
Brentuximab vedotin	The serum concentration of Brentuximab vedotin can be increased when it is combined with Nelfinavir.	Approved, Investigational
Brexpiprazole	The serum concentration of Brexpiprazole can be increased when it is combined with Nelfinavir.	Approved, Investigational
Brigatinib	The serum concentration of Brigatinib can be increased when it is combined with Nelfinavir.	Approved, Investigational
Brinzolamide	The serum concentration of Brinzolamide can be increased when it is combined with Nelfinavir.	Approved
Brivaracetam	The metabolism of Brivaracetam can be decreased when combined with Nelfinavir.	Approved, Investigational
Bromazepam	The metabolism of Bromazepam can be decreased when combined with Nelfinavir.	Approved, Illicit, Investigational
Bromocriptine	The risk or severity of adverse effects can be increased when Bromocriptine is combined with Nelfinavir.	Approved, Investigational
Brompheniramine	The metabolism of Brompheniramine can be decreased when combined with Nelfinavir.	Approved
Budesonide	The serum concentration of Budesonide can be increased when it is combined with Nelfinavir.	Approved
Buformin	The therapeutic efficacy of Buformin can be decreased when used in combination with Nelfinavir.	Investigational, Withdrawn
Bupivacaine	The metabolism of Bupivacaine can be decreased when combined with Nelfinavir.	Approved, Investigational
Buprenorphine	The metabolism of Buprenorphine can be decreased when combined with Nelfinavir.	Approved, Illicit, Investigational, Vet Approved
Bupropion	The metabolism of Bupropion can be decreased when combined with Nelfinavir.	Approved
Buspirone	The metabolism of Buspirone can be decreased when combined with Nelfinavir.	Approved, Investigational
Busulfan	The metabolism of Busulfan can be decreased when combined with Nelfinavir.	Approved, Investigational
Butriptyline	The serum concentration of Butriptyline can be increased when it is combined with Nelfinavir.	Approved
Cabazitaxel	The serum concentration of Cabazitaxel can be increased when it is combined with Nelfinavir.	Approved
Cabergoline	The risk or severity of adverse effects can be increased when Cabergoline is combined with Nelfinavir.	Approved
Cabozantinib	The serum concentration of Cabozantinib can be increased when it is combined with Nelfinavir.	Approved, Investigational
Caffeine	The metabolism of Caffeine can be decreased when combined with Nelfinavir.	Approved
Calcitriol	The metabolism of Calcitriol can be decreased when combined with Nelfinavir.	Approved, Nutraceutical
Canagliflozin	The metabolism of Canagliflozin can be decreased when combined with Nelfinavir.	Approved
Cannabidiol	The metabolism of Cannabidiol can be decreased when combined with Nelfinavir.	Approved, Investigational
Carbamazepine	The serum concentration of Carbamazepine can be increased when it is combined with Nelfinavir.	Approved, Investigational
Carbinoxamine	The metabolism of Carbinoxamine can be decreased when combined with Nelfinavir.	Approved
Carboxyamidotriazole	The metabolism of Carboxyamidotriazole can be decreased when combined with Nelfinavir.	Investigational
Carbutamide	The therapeutic efficacy of Carbutamide can be decreased when used in combination with Nelfinavir.	Experimental
Cariprazine	The metabolism of Cariprazine can be decreased when combined with Nelfinavir.	Approved, Investigational
Caroverine	The metabolism of Caroverine can be decreased when combined with Nelfinavir.	Experimental
Carvedilol	The serum concentration of Carvedilol can be decreased when it is combined with Nelfinavir.	Approved, Investigational
Castanospermine	The therapeutic efficacy of Castanospermine can be decreased when used in combination with Nelfinavir.	Experimental
Celecoxib	The metabolism of Celecoxib can be decreased when combined with Nelfinavir.	Approved, Investigational
Celiprolol	The metabolism of Celiprolol can be decreased when combined with Nelfinavir.	Approved, Investigational
Cephalexin	The metabolism of Cephalexin can be decreased when combined with Nelfinavir.	Approved, Investigational, Vet Approved
Ceritinib	The serum concentration of Ceritinib can be increased when it is combined with Nelfinavir.	Approved
Cerivastatin	The serum concentration of Cerivastatin can be increased when it is combined with Nelfinavir.	Approved, Withdrawn
Cetirizine	The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Cetirizine.	Approved
Cevimeline	The metabolism of Cevimeline can be decreased when combined with Nelfinavir.	Approved
Chenodeoxycholic acid	The metabolism of Chenodeoxycholic acid can be decreased when combined with Nelfinavir.	Approved
Chloramphenicol	The metabolism of Nelfinavir can be decreased when combined with Chloramphenicol.	Approved, Vet Approved
Chlordiazepoxide	The metabolism of Chlordiazepoxide can be decreased when combined with Nelfinavir.	Approved, Illicit, Investigational
Chlormadinone	The serum concentration of Chlormadinone can be decreased when it is combined with Nelfinavir.	Experimental
Chloroquine	The metabolism of Chloroquine can be decreased when combined with Nelfinavir.	Approved, Investigational, Vet Approved
Chlorphenamine	The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Chlorphenamine.	Approved
Chlorpromazine	The metabolism of Chlorpromazine can be decreased when combined with Nelfinavir.	Approved, Investigational, Vet Approved
Chlorzoxazone	The metabolism of Chlorzoxazone can be decreased when combined with Nelfinavir.	Approved
Cholecalciferol	The metabolism of Cholecalciferol can be decreased when combined with Nelfinavir.	Approved, Nutraceutical
Ciclesonide	The metabolism of Ciclesonide can be decreased when combined with Nelfinavir.	Approved, Investigational
Ciglitazone	The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Nelfinavir.	Experimental
Cilnidipine	The metabolism of Cilnidipine can be decreased when combined with Nelfinavir.	Approved, Investigational
Cilostazol	The serum concentration of Cilostazol can be increased when it is combined with Nelfinavir.	Approved, Investigational
Cimetidine	Cimetidine can cause a decrease in the absorption of Nelfinavir resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved, Investigational
Cinacalcet	The metabolism of Cinacalcet can be decreased when combined with Nelfinavir.	Approved
Cinnarizine	The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Cinnarizine.	Approved, Investigational
Ciprofloxacin	The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Ciprofloxacin.	Approved, Investigational
Cisapride	The metabolism of Cisapride can be decreased when combined with Nelfinavir.	Approved, Investigational, Withdrawn
Citalopram	The serum concentration of Citalopram can be increased when it is combined with Nelfinavir.	Approved
Clarithromycin	The therapeutic efficacy of Clarithromycin can be decreased when used in combination with Nelfinavir.	Approved
Clemastine	The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Clemastine.	Approved, Investigational
Clevidipine	The metabolism of Clevidipine can be decreased when combined with Nelfinavir.	Approved, Investigational
Clindamycin	The metabolism of Clindamycin can be decreased when combined with Nelfinavir.	Approved, Vet Approved
Clobazam	The metabolism of Clobazam can be decreased when combined with Nelfinavir.	Approved, Illicit
Clobetasol	The serum concentration of Clobetasol can be increased when it is combined with Nelfinavir.	Approved, Investigational
Clobetasol propionate	The serum concentration of Clobetasol propionate can be increased when it is combined with Nelfinavir.	Approved
Clobetasone	The serum concentration of Clobetasone can be increased when it is combined with Nelfinavir.	Approved
Clocortolone	The serum concentration of Clocortolone can be increased when it is combined with Nelfinavir.	Approved
Clofazimine	The metabolism of Clofazimine can be decreased when combined with Nelfinavir.	Approved, Investigational
Clofibrate	The metabolism of Clofibrate can be decreased when combined with Nelfinavir.	Approved, Investigational
clomethiazole	The metabolism of clomethiazole can be decreased when combined with Nelfinavir.	Investigational
Clomipramine	The metabolism of Clomipramine can be decreased when combined with Nelfinavir.	Approved, Investigational, Vet Approved
Clonazepam	The metabolism of Clonazepam can be decreased when combined with Nelfinavir.	Approved, Illicit
Clonidine	The metabolism of Clonidine can be decreased when combined with Nelfinavir.	Approved
Clopidogrel	The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Nelfinavir resulting in a loss in efficacy.	Approved
Clorazepate	The metabolism of Clorazepate can be decreased when combined with Nelfinavir.	Approved, Illicit
Clotiazepam	The metabolism of Clotiazepam can be decreased when combined with Nelfinavir.	Approved, Illicit
Clotrimazole	The metabolism of Nelfinavir can be decreased when combined with Clotrimazole.	Approved, Vet Approved
Clozapine	The metabolism of Clozapine can be decreased when combined with Nelfinavir.	Approved
Cobicistat	The metabolism of Nelfinavir can be decreased when combined with Cobicistat.	Approved
Cobimetinib	The serum concentration of Cobimetinib can be increased when it is combined with Nelfinavir.	Approved, Investigational
Cocaine	The metabolism of Cocaine can be decreased when combined with Nelfinavir.	Approved, Illicit
Codeine	The serum concentration of Codeine can be decreased when it is combined with Nelfinavir.	Approved, Illicit
Colchicine	The serum concentration of Colchicine can be increased when it is combined with Nelfinavir.	Approved
Conivaptan	The serum concentration of Conivaptan can be increased when it is combined with Nelfinavir.	Approved, Investigational
Conjugated estrogens	The metabolism of Conjugated estrogens can be decreased when combined with Nelfinavir.	Approved
Copanlisib	The metabolism of Copanlisib can be decreased when combined with Nelfinavir.	Approved, Investigational
Cortexolone 17α-propionate	The serum concentration of Cortexolone 17α-propionate can be increased when it is combined with Nelfinavir.	Investigational
Corticosterone	The serum concentration of Corticosterone can be increased when it is combined with Nelfinavir.	Experimental
Cortisone acetate	The metabolism of Cortisone acetate can be decreased when combined with Nelfinavir.	Approved, Investigational
Crizotinib	The serum concentration of Crizotinib can be increased when it is combined with Nelfinavir.	Approved
Curcumin	The metabolism of Nelfinavir can be decreased when combined with Curcumin.	Approved, Investigational
Cyclandelate	The metabolism of Cyclandelate can be decreased when combined with Nelfinavir.	Approved
Cyclobenzaprine	The serum concentration of Cyclobenzaprine can be decreased when it is combined with Nelfinavir.	Approved
Cyclophosphamide	The risk or severity of adverse effects can be increased when Nelfinavir is combined with Cyclophosphamide.	Approved, Investigational
Cyclosporine	The metabolism of Cyclosporine can be decreased when combined with Nelfinavir.	Approved, Investigational, Vet Approved
Cyproterone acetate	The serum concentration of Cyproterone acetate can be decreased when it is combined with Nelfinavir.	Approved, Investigational
Cytarabine	The metabolism of Cytarabine can be decreased when combined with Nelfinavir.	Approved, Investigational
Dabigatran etexilate	The serum concentration of Dabigatran etexilate can be decreased when it is combined with Nelfinavir.	Approved
Dabrafenib	The serum concentration of Nelfinavir can be decreased when it is combined with Dabrafenib.	Approved, Investigational
Daclatasvir	The serum concentration of Daclatasvir can be increased when it is combined with Nelfinavir.	Approved, Investigational
Dantrolene	The metabolism of Dantrolene can be decreased when combined with Nelfinavir.	Approved, Investigational
Dapagliflozin	The metabolism of Dapagliflozin can be decreased when combined with Nelfinavir.	Approved
Dapoxetine	The serum concentration of Dapoxetine can be increased when it is combined with Nelfinavir.	Investigational
Dapsone	The metabolism of Dapsone can be decreased when combined with Nelfinavir.	Approved, Investigational
Darifenacin	The metabolism of Darifenacin can be decreased when combined with Nelfinavir.	Approved, Investigational
Darodipine	The metabolism of Darodipine can be decreased when combined with Nelfinavir.	Experimental
Darunavir	The metabolism of Darunavir can be decreased when combined with Nelfinavir.	Approved
Dasabuvir	The metabolism of Dasabuvir can be decreased when combined with Nelfinavir.	Approved
Dasatinib	The serum concentration of Dasatinib can be increased when it is combined with Nelfinavir.	Approved, Investigational
Daunorubicin	The metabolism of Daunorubicin can be decreased when combined with Nelfinavir.	Approved
Deferasirox	The serum concentration of Nelfinavir can be decreased when it is combined with Deferasirox.	Approved, Investigational
Deflazacort	The metabolism of Deflazacort can be decreased when combined with Nelfinavir.	Approved, Investigational
Delamanid	Nelfinavir may increase the QTc-prolonging activities of Delamanid.	Approved, Investigational
Delavirdine	The serum concentration of Delavirdine can be decreased when it is combined with Nelfinavir.	Approved
Deoxyspergualin	The therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Nelfinavir.	Investigational
Desipramine	The serum concentration of Desipramine can be increased when it is combined with Nelfinavir.	Approved, Investigational
Desogestrel	The serum concentration of Desogestrel can be decreased when it is combined with Nelfinavir.	Approved
Desonide	The serum concentration of Desonide can be increased when it is combined with Nelfinavir.	Approved, Investigational
Desoximetasone	The serum concentration of Desoximetasone can be increased when it is combined with Nelfinavir.	Approved
Desoxycorticosterone acetate	The serum concentration of Desoxycorticosterone acetate can be increased when it is combined with Nelfinavir.	Approved
Desoxycorticosterone Pivalate	The serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Nelfinavir.	Experimental, Vet Approved
Desvenlafaxine	The metabolism of Desvenlafaxine can be decreased when combined with Nelfinavir.	Approved, Investigational
Deutetrabenazine	The metabolism of Deutetrabenazine can be decreased when combined with Nelfinavir.	Approved, Investigational
Dexamethasone	The metabolism of Dexamethasone can be decreased when combined with Nelfinavir.	Approved, Investigational, Vet Approved
Dexamethasone isonicotinate	The serum concentration of Dexamethasone isonicotinate can be increased when it is combined with Nelfinavir.	Vet Approved
Dexbrompheniramine	The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Dexbrompheniramine.	Approved
Dexchlorpheniramine maleate	The metabolism of Dexchlorpheniramine maleate can be decreased when combined with Nelfinavir.	Approved
Dexlansoprazole	The serum concentration of the active metabolites of Nelfinavir can be reduced when Nelfinavir is used in combination with Dexlansoprazole resulting in a loss in efficacy.	Approved, Investigational
Dexniguldipine	The metabolism of Dexniguldipine can be decreased when combined with Nelfinavir.	Experimental
Dexrabeprazole	The serum concentration of the active metabolites of Nelfinavir can be reduced when Nelfinavir is used in combination with Dexrabeprazole resulting in a loss in efficacy.	Experimental
Dextromethorphan	The metabolism of Dextromethorphan can be decreased when combined with Nelfinavir.	Approved
Dextropropoxyphene	The metabolism of Dextropropoxyphene can be decreased when combined with Nelfinavir.	Approved, Illicit, Investigational, Withdrawn
Dexverapamil	The metabolism of Dexverapamil can be decreased when combined with Nelfinavir.	Experimental
Diazepam	The metabolism of Diazepam can be decreased when combined with Nelfinavir.	Approved, Illicit, Investigational, Vet Approved
Dibenzepin	The serum concentration of Dibenzepin can be increased when it is combined with Nelfinavir.	Experimental
Diclofenac	The serum concentration of Diclofenac can be decreased when it is combined with Nelfinavir.	Approved, Vet Approved
Dienogest	The serum concentration of Dienogest can be decreased when it is combined with Nelfinavir.	Approved
Diethylstilbestrol	The serum concentration of Diethylstilbestrol can be decreased when it is combined with Nelfinavir.	Approved, Investigational
Diflorasone	The serum concentration of Diflorasone can be increased when it is combined with Nelfinavir.	Approved
Difluocortolone	The serum concentration of Difluocortolone can be increased when it is combined with Nelfinavir.	Approved, Investigational, Withdrawn
Difluprednate	The serum concentration of Difluprednate can be increased when it is combined with Nelfinavir.	Approved
Digitoxin	The metabolism of Digitoxin can be decreased when combined with Nelfinavir.	Approved, Investigational
Digoxin	The serum concentration of Digoxin can be increased when it is combined with Nelfinavir.	Approved
Dihydro-alpha-ergocryptine	The metabolism of Dihydro-alpha-ergocryptine can be decreased when combined with Nelfinavir.	Approved
Dihydrocodeine	The metabolism of Dihydrocodeine can be decreased when combined with Nelfinavir.	Approved, Illicit
Dihydroergocornine	The risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Nelfinavir.	Approved
Dihydroergocristine	The risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Nelfinavir.	Approved, Experimental
Dihydroergocryptine	The risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Nelfinavir.	Experimental
Dihydroergotamine	The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Nelfinavir.	Approved, Investigational
Diltiazem	The metabolism of Diltiazem can be decreased when combined with Nelfinavir.	Approved, Investigational
Dimenhydrinate	The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Dimenhydrinate.	Approved
Dimetacrine	The serum concentration of Dimetacrine can be increased when it is combined with Nelfinavir.	Approved, Withdrawn
Diphenhydramine	The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Diphenhydramine.	Approved, Investigational
Disopyramide	The metabolism of Disopyramide can be decreased when combined with Nelfinavir.	Approved
Disulfiram	The metabolism of Disulfiram can be decreased when combined with Nelfinavir.	Approved
Docetaxel	The metabolism of Docetaxel can be decreased when combined with Nelfinavir.	Approved, Investigational
Dofetilide	The serum concentration of Dofetilide can be increased when it is combined with Nelfinavir.	Approved, Investigational
Dolasetron	The metabolism of Dolasetron can be decreased when combined with Nelfinavir.	Approved, Investigational
Domperidone	The serum concentration of Domperidone can be increased when it is combined with Nelfinavir.	Approved, Investigational, Vet Approved
Donepezil	The metabolism of Donepezil can be decreased when combined with Nelfinavir.	Approved
Dorzolamide	The metabolism of Dorzolamide can be decreased when combined with Nelfinavir.	Approved
Dosulepin	The serum concentration of Dosulepin can be increased when it is combined with Nelfinavir.	Approved
Dotarizine	The metabolism of Dotarizine can be decreased when combined with Nelfinavir.	Investigational
Doxazosin	The serum concentration of Nelfinavir can be increased when it is combined with Doxazosin.	Approved
Doxepin	The serum concentration of Nelfinavir can be decreased when it is combined with Doxepin.	Approved, Investigational
Doxorubicin	The serum concentration of Doxorubicin can be increased when it is combined with Nelfinavir.	Approved, Investigational
Doxorubicin	The metabolism of Doxorubicin can be decreased when combined with Nelfinavir.	Approved, Investigational
Doxycycline	The metabolism of Nelfinavir can be decreased when combined with Doxycycline.	Approved, Investigational, Vet Approved
Doxylamine	The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Doxylamine.	Approved, Vet Approved
Dronabinol	The serum concentration of Dronabinol can be increased when it is combined with Nelfinavir.	Approved, Illicit
Dronedarone	The serum concentration of Dronedarone can be increased when it is combined with Nelfinavir.	Approved
Droperidol	Nelfinavir may increase the QTc-prolonging activities of Droperidol.	Approved, Vet Approved
Drospirenone	The serum concentration of Drospirenone can be decreased when it is combined with Nelfinavir.	Approved
Dulaglutide	The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Nelfinavir.	Approved, Investigational
Dutasteride	The serum concentration of Dutasteride can be increased when it is combined with Nelfinavir.	Approved, Investigational
Dyphylline	The serum concentration of Dyphylline can be decreased when it is combined with Nelfinavir.	Approved
Edoxaban	The serum concentration of Edoxaban can be increased when it is combined with Nelfinavir.	Approved
Efavirenz	The metabolism of Efavirenz can be decreased when combined with Nelfinavir.	Approved, Investigational
Efonidipine	The metabolism of Efonidipine can be decreased when combined with Nelfinavir.	Approved, Investigational
Elbasvir	The metabolism of Elbasvir can be decreased when combined with Nelfinavir.	Approved
Eletriptan	The serum concentration of Eletriptan can be increased when it is combined with Nelfinavir.	Approved, Investigational
Eliglustat	The serum concentration of Eliglustat can be increased when it is combined with Nelfinavir.	Approved
Elvitegravir	The metabolism of Elvitegravir can be decreased when combined with Nelfinavir.	Approved
Emopamil	The metabolism of Emopamil can be decreased when combined with Nelfinavir.	Experimental
Empagliflozin	The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Nelfinavir.	Approved
Enalapril	The metabolism of Enalapril can be decreased when combined with Nelfinavir.	Approved, Vet Approved
Enasidenib	The metabolism of Enasidenib can be decreased when combined with Nelfinavir.	Approved, Investigational
Enfuvirtide	The serum concentration of Enfuvirtide can be increased when it is combined with Nelfinavir.	Approved, Investigational
Englitazone	The therapeutic efficacy of Englitazone can be decreased when used in combination with Nelfinavir.	Experimental
Enzalutamide	The serum concentration of Nelfinavir can be decreased when it is combined with Enzalutamide.	Approved
Eperisone	The metabolism of Eperisone can be decreased when combined with Nelfinavir.	Approved, Investigational
Epinastine	The serum concentration of Nelfinavir can be decreased when it is combined with Epinastine.	Approved, Investigational
Eplerenone	The serum concentration of Eplerenone can be increased when it is combined with Nelfinavir.	Approved
Equilenin	The serum concentration of Equilenin can be increased when it is combined with Nelfinavir.	Experimental
Equilin	The serum concentration of Equilin can be increased when it is combined with Nelfinavir.	Approved
Ergocalciferol	The metabolism of Ergocalciferol can be decreased when combined with Nelfinavir.	Approved, Nutraceutical
Ergoloid mesylate	The serum concentration of Ergoloid mesylate can be increased when it is combined with Nelfinavir.	Approved
Ergonovine	The risk or severity of adverse effects can be increased when Ergonovine is combined with Nelfinavir.	Approved
Ergotamine	The risk or severity of adverse effects can be increased when Ergotamine is combined with Nelfinavir.	Approved
Erlotinib	The serum concentration of Erlotinib can be increased when it is combined with Nelfinavir.	Approved, Investigational
Erythromycin	The metabolism of Erythromycin can be decreased when combined with Nelfinavir.	Approved, Investigational, Vet Approved
Escitalopram	The metabolism of Escitalopram can be decreased when combined with Nelfinavir.	Approved, Investigational
Eslicarbazepine acetate	The metabolism of Nelfinavir can be decreased when combined with Eslicarbazepine acetate.	Approved
Esomeprazole	The serum concentration of the active metabolites of Nelfinavir can be reduced when Nelfinavir is used in combination with Esomeprazole resulting in a loss in efficacy.	Approved, Investigational
Estazolam	The serum concentration of Estazolam can be increased when it is combined with Nelfinavir.	Approved, Illicit
Estradiol	The metabolism of Estradiol can be decreased when combined with Nelfinavir.	Approved, Investigational, Vet Approved
Estradiol acetate	The metabolism of Estradiol acetate can be decreased when combined with Nelfinavir.	Approved, Investigational, Vet Approved
Estradiol benzoate	The metabolism of Estradiol benzoate can be decreased when combined with Nelfinavir.	Approved, Investigational, Vet Approved
Estradiol cypionate	The metabolism of Estradiol cypionate can be decreased when combined with Nelfinavir.	Approved, Investigational, Vet Approved
Estradiol dienanthate	The metabolism of Estradiol dienanthate can be decreased when combined with Nelfinavir.	Approved, Investigational, Vet Approved
Estradiol valerate	The metabolism of Estradiol valerate can be decreased when combined with Nelfinavir.	Approved, Investigational, Vet Approved
Estramustine	The metabolism of Estramustine can be decreased when combined with Nelfinavir.	Approved, Investigational
Estrogens, esterified	The metabolism of Estrogens, esterified can be decreased when combined with Nelfinavir.	Approved
Estrone	The metabolism of Estrone can be decreased when combined with Nelfinavir.	Approved
Estrone sulfate	The metabolism of Estrone sulfate can be decreased when combined with Nelfinavir.	Approved
Eszopiclone	The metabolism of Eszopiclone can be decreased when combined with Nelfinavir.	Approved, Investigational
Ethanol	The metabolism of Ethanol can be decreased when combined with Nelfinavir.	Approved
Ethinyl Estradiol	The metabolism of Ethinyl Estradiol can be decreased when combined with Nelfinavir.	Approved
Ethosuximide	The metabolism of Ethosuximide can be decreased when combined with Nelfinavir.	Approved
Ethylmorphine	The metabolism of Ethylmorphine can be decreased when combined with Nelfinavir.	Approved, Illicit
Ethynodiol diacetate	The serum concentration of Ethynodiol diacetate can be decreased when it is combined with Nelfinavir.	Approved
Etizolam	The serum concentration of Etizolam can be increased when it is combined with Nelfinavir.	Approved
Etonogestrel	The serum concentration of Etonogestrel can be decreased when it is combined with Nelfinavir.	Approved, Investigational
Etoposide	The metabolism of Etoposide can be decreased when combined with Nelfinavir.	Approved
Etoricoxib	The metabolism of Etoricoxib can be decreased when combined with Nelfinavir.	Approved, Investigational
Etravirine	The serum concentration of Etravirine can be decreased when it is combined with Nelfinavir.	Approved
Everolimus	The serum concentration of Everolimus can be increased when it is combined with Nelfinavir.	Approved
Exemestane	The metabolism of Exemestane can be decreased when combined with Nelfinavir.	Approved, Investigational
Exenatide	The therapeutic efficacy of Exenatide can be decreased when used in combination with Nelfinavir.	Approved, Investigational
Famciclovir	The metabolism of Famciclovir can be decreased when combined with Nelfinavir.	Approved, Investigational
Famotidine	Famotidine can cause a decrease in the absorption of Nelfinavir resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Felbamate	The metabolism of Felbamate can be decreased when combined with Nelfinavir.	Approved
Felodipine	The metabolism of Felodipine can be decreased when combined with Nelfinavir.	Approved, Investigational
Fendiline	The metabolism of Fendiline can be decreased when combined with Nelfinavir.	Withdrawn
Fenofibrate	The metabolism of Fenofibrate can be decreased when combined with Nelfinavir.	Approved
Fentanyl	The serum concentration of Fentanyl can be increased when it is combined with Nelfinavir.	Approved, Illicit, Investigational, Vet Approved
Fesoterodine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Nelfinavir.	Approved
Finasteride	The metabolism of Finasteride can be decreased when combined with Nelfinavir.	Approved
Fingolimod	The metabolism of Fingolimod can be decreased when combined with Nelfinavir.	Approved, Investigational
Fish oil	The metabolism of Fish oil can be decreased when combined with Nelfinavir.	Approved, Nutraceutical
Flecainide	Nelfinavir may increase the QTc-prolonging activities of Flecainide.	Approved, Withdrawn
Flibanserin	The serum concentration of Flibanserin can be increased when it is combined with Nelfinavir.	Approved, Investigational
Fluasterone	The serum concentration of Fluasterone can be increased when it is combined with Nelfinavir.	Investigational
Fluconazole	The metabolism of Nelfinavir can be decreased when combined with Fluconazole.	Approved, Investigational
Fludrocortisone	The serum concentration of Fludrocortisone can be increased when it is combined with Nelfinavir.	Approved, Investigational
Flumethasone	The serum concentration of Flumethasone can be increased when it is combined with Nelfinavir.	Approved, Vet Approved
Flunarizine	The metabolism of Flunarizine can be decreased when combined with Nelfinavir.	Approved
Flunisolide	The metabolism of Flunisolide can be decreased when combined with Nelfinavir.	Approved, Investigational
Flunitrazepam	The metabolism of Flunitrazepam can be decreased when combined with Nelfinavir.	Approved, Illicit
Fluocinolone Acetonide	The serum concentration of Fluocinolone Acetonide can be increased when it is combined with Nelfinavir.	Approved, Investigational, Vet Approved
Fluocinonide	The serum concentration of Fluocinonide can be increased when it is combined with Nelfinavir.	Approved, Investigational
Fluocortolone	The serum concentration of Fluocortolone can be increased when it is combined with Nelfinavir.	Approved, Withdrawn
Fluorometholone	The metabolism of Fluorometholone can be decreased when combined with Nelfinavir.	Approved, Investigational
Fluoxetine	The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Fluoxetine.	Approved, Vet Approved
Flupentixol	Nelfinavir may increase the QTc-prolonging activities of Flupentixol.	Approved, Investigational, Withdrawn
Fluprednidene	The serum concentration of Fluprednidene can be increased when it is combined with Nelfinavir.	Approved, Withdrawn
Fluprednisolone	The serum concentration of Fluprednisolone can be increased when it is combined with Nelfinavir.	Approved
Flurandrenolide	The serum concentration of Flurandrenolide can be increased when it is combined with Nelfinavir.	Approved
Flurazepam	The metabolism of Flurazepam can be decreased when combined with Nelfinavir.	Approved, Illicit, Investigational
Fluspirilene	The metabolism of Fluspirilene can be decreased when combined with Nelfinavir.	Approved, Investigational
Flutamide	The metabolism of Flutamide can be decreased when combined with Nelfinavir.	Approved, Investigational
Fluticasone	The serum concentration of Fluticasone can be increased when it is combined with Nelfinavir.	Approved, Experimental, Investigational
Fluticasone furoate	The metabolism of Fluticasone furoate can be decreased when combined with Nelfinavir.	Approved
Fluticasone propionate	The serum concentration of Fluticasone propionate can be increased when it is combined with Nelfinavir.	Approved
Fluvastatin	The serum concentration of Fluvastatin can be decreased when it is combined with Nelfinavir.	Approved
Fluvoxamine	The serum concentration of Nelfinavir can be increased when it is combined with Fluvoxamine.	Approved, Investigational
Formestane	The serum concentration of Formestane can be increased when it is combined with Nelfinavir.	Approved, Investigational, Withdrawn
Fosamprenavir	The metabolism of Fosamprenavir can be decreased when combined with Nelfinavir.	Approved
Fosaprepitant	The serum concentration of Nelfinavir can be increased when it is combined with Fosaprepitant.	Approved
Fosnetupitant	The metabolism of Fosnetupitant can be decreased when combined with Nelfinavir.	Approved
Fosphenytoin	The serum concentration of Nelfinavir can be decreased when it is combined with Fosphenytoin.	Approved, Investigational
Fostamatinib	The metabolism of Fostamatinib can be decreased when combined with Nelfinavir.	Approved, Investigational
Fulvestrant	The metabolism of Fulvestrant can be decreased when combined with Nelfinavir.	Approved, Investigational
Fusidic Acid	The serum concentration of Nelfinavir can be increased when it is combined with Fusidic Acid.	Approved, Investigational
Gabapentin	The metabolism of Gabapentin can be decreased when combined with Nelfinavir.	Approved, Investigational
Gadobenic acid	Nelfinavir may increase the QTc-prolonging activities of Gadobenic acid.	Approved, Investigational
Galantamine	The metabolism of Galantamine can be decreased when combined with Nelfinavir.	Approved
Gallopamil	The metabolism of Gallopamil can be decreased when combined with Nelfinavir.	Investigational
Garlic	The serum concentration of Nelfinavir can be decreased when it is combined with Garlic.	Approved, Nutraceutical
Gefitinib	The metabolism of Gefitinib can be decreased when combined with Nelfinavir.	Approved, Investigational
Gemfibrozil	The metabolism of Gemfibrozil can be decreased when combined with Nelfinavir.	Approved
Gemifloxacin	Nelfinavir may increase the QTc-prolonging activities of Gemifloxacin.	Approved, Investigational
Gestodene	The serum concentration of Gestodene can be decreased when it is combined with Nelfinavir.	Approved, Investigational
Gestrinone	The serum concentration of Gestrinone can be decreased when it is combined with Nelfinavir.	Approved
Glibornuride	The therapeutic efficacy of Glibornuride can be decreased when used in combination with Nelfinavir.	Investigational, Withdrawn
Glimepiride	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Nelfinavir.	Approved
Glipizide	The serum concentration of Glipizide can be decreased when it is combined with Nelfinavir.	Approved, Investigational
Gliquidone	The therapeutic efficacy of Gliquidone can be decreased when used in combination with Nelfinavir.	Approved, Investigational
Glyburide	The metabolism of Glyburide can be decreased when combined with Nelfinavir.	Approved
Glycerin	The serum concentration of Nelfinavir can be increased when it is combined with Glycerin.	Approved, Investigational
Goserelin	Nelfinavir may increase the QTc-prolonging activities of Goserelin.	Approved
Granisetron	The metabolism of Granisetron can be decreased when combined with Nelfinavir.	Approved, Investigational
Grazoprevir	The metabolism of Grazoprevir can be decreased when combined with Nelfinavir.	Approved
Grepafloxacin	The metabolism of Grepafloxacin can be decreased when combined with Nelfinavir.	Approved, Investigational, Withdrawn
Guanfacine	The serum concentration of Guanfacine can be increased when it is combined with Nelfinavir.	Approved, Investigational
Gusperimus	The therapeutic efficacy of Gusperimus can be decreased when used in combination with Nelfinavir.	Investigational
Halcinonide	The serum concentration of Halcinonide can be increased when it is combined with Nelfinavir.	Approved, Investigational, Withdrawn
Halofantrine	The serum concentration of Halofantrine can be increased when it is combined with Nelfinavir.	Approved
Haloperidol	The metabolism of Haloperidol can be decreased when combined with Nelfinavir.	Approved
Halothane	The metabolism of Halothane can be decreased when combined with Nelfinavir.	Approved, Vet Approved
HE3286	The serum concentration of HE3286 can be increased when it is combined with Nelfinavir.	Investigational
Hexobarbital	The metabolism of Hexobarbital can be decreased when combined with Nelfinavir.	Approved
Histamine	The metabolism of Histamine can be decreased when combined with Nelfinavir.	Approved, Investigational
Hydrocortisone	The metabolism of Hydrocortisone can be decreased when combined with Nelfinavir.	Approved, Vet Approved
Hydrocortisone acetate	The metabolism of Hydrocortisone acetate can be decreased when combined with Nelfinavir.	Approved, Vet Approved
Hydromorphone	The metabolism of Hydromorphone can be decreased when combined with Nelfinavir.	Approved, Illicit
Hydroxyprogesterone caproate	The serum concentration of Hydroxyprogesterone caproate can be decreased when it is combined with Nelfinavir.	Approved, Investigational
Ibrutinib	The serum concentration of Ibrutinib can be increased when it is combined with Nelfinavir.	Approved
Ibuprofen	The serum concentration of Ibuprofen can be decreased when it is combined with Nelfinavir.	Approved
Ibutilide	Nelfinavir may increase the QTc-prolonging activities of Ibutilide.	Approved
Icotinib	The metabolism of Icotinib can be decreased when combined with Nelfinavir.	Approved, Investigational
Idelalisib	The serum concentration of Idelalisib can be increased when it is combined with Nelfinavir.	Approved
Ifosfamide	The serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Nelfinavir resulting in a loss in efficacy.	Approved
Iloperidone	The serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Nelfinavir.	Approved
Imatinib	The serum concentration of Imatinib can be increased when it is combined with Nelfinavir.	Approved
Imidafenacin	The serum concentration of Imidafenacin can be increased when it is combined with Nelfinavir.	Approved, Investigational
Imipramine	The metabolism of Imipramine can be decreased when combined with Nelfinavir.	Approved
Imiquimod	The metabolism of Imiquimod can be decreased when combined with Nelfinavir.	Approved, Investigational
Indacaterol	The metabolism of Indacaterol can be decreased when combined with Nelfinavir.	Approved
Indapamide	The metabolism of Indapamide can be decreased when combined with Nelfinavir.	Approved
Indinavir	The metabolism of Indinavir can be decreased when combined with Nelfinavir.	Approved
Insulin Aspart	The therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Nelfinavir.	Approved
Insulin Detemir	The therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Nelfinavir.	Approved
Insulin Glargine	The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Nelfinavir.	Approved
Insulin Glulisine	The therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Nelfinavir.	Approved
Insulin Human	The therapeutic efficacy of Insulin Human can be decreased when used in combination with Nelfinavir.	Approved, Investigational
Insulin Lispro	The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Nelfinavir.	Approved
Insulin Pork	The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Nelfinavir.	Approved
Ipecac	The metabolism of Ipecac can be decreased when combined with Nelfinavir.	Approved, Withdrawn
Ipratropium	The metabolism of Ipratropium can be decreased when combined with Nelfinavir.	Approved
Iprindole	The serum concentration of Iprindole can be increased when it is combined with Nelfinavir.	Experimental
Irinotecan	The serum concentration of Irinotecan can be increased when it is combined with Nelfinavir.	Approved, Investigational
Isavuconazole	The serum concentration of Isavuconazole can be increased when it is combined with Nelfinavir.	Approved, Investigational
Isavuconazonium	The serum concentration of the active metabolites of Isavuconazonium can be increased when Isavuconazonium is used in combination with Nelfinavir.	Approved, Investigational
Isoniazid	The metabolism of Nelfinavir can be decreased when combined with Isoniazid.	Approved, Investigational
Isosorbide Dinitrate	The metabolism of Isosorbide Dinitrate can be decreased when combined with Nelfinavir.	Approved, Investigational
Isosorbide Mononitrate	The metabolism of Isosorbide Mononitrate can be decreased when combined with Nelfinavir.	Approved
Isradipine	The metabolism of Isradipine can be decreased when combined with Nelfinavir.	Approved, Investigational
Istaroxime	The serum concentration of Istaroxime can be increased when it is combined with Nelfinavir.	Investigational
Itraconazole	The metabolism of Itraconazole can be decreased when combined with Nelfinavir.	Approved, Investigational
Ivabradine	The serum concentration of Ivabradine can be increased when it is combined with Nelfinavir.	Approved
Ivacaftor	The serum concentration of Ivacaftor can be increased when it is combined with Nelfinavir.	Approved
Ivermectin	The metabolism of Ivermectin can be decreased when combined with Nelfinavir.	Approved, Investigational, Vet Approved
Ixabepilone	The serum concentration of Ixabepilone can be increased when it is combined with Nelfinavir.	Approved, Investigational
Ixazomib	The metabolism of Ixazomib can be decreased when combined with Nelfinavir.	Approved, Investigational
Ketamine	The metabolism of Ketamine can be decreased when combined with Nelfinavir.	Approved, Vet Approved
Ketazolam	The metabolism of Ketazolam can be decreased when combined with Nelfinavir.	Approved
Ketobemidone	The metabolism of Ketobemidone can be decreased when combined with Nelfinavir.	Approved, Investigational
Ketoconazole	The metabolism of Ketoconazole can be decreased when combined with Nelfinavir.	Approved, Investigational
Lacidipine	The serum concentration of Lacidipine can be increased when it is combined with Nelfinavir.	Approved, Investigational
Lacosamide	The serum concentration of Lacosamide can be increased when it is combined with Nelfinavir.	Approved
Lafutidine	The serum concentration of Nelfinavir can be decreased when it is combined with Lafutidine.	Investigational
Lamivudine	The serum concentration of Lamivudine can be increased when it is combined with Nelfinavir.	Approved, Investigational
Lamotrigine	The serum concentration of Lamotrigine can be decreased when it is combined with Nelfinavir.	Approved, Investigational
Lansoprazole	The serum concentration of the active metabolites of Nelfinavir can be reduced when Nelfinavir is used in combination with Lansoprazole resulting in a loss in efficacy.	Approved, Investigational
Lapatinib	The serum concentration of Lapatinib can be increased when it is combined with Nelfinavir.	Approved, Investigational
Laquinimod	The metabolism of Laquinimod can be decreased when combined with Nelfinavir.	Investigational
Lavoltidine	The serum concentration of Nelfinavir can be decreased when it is combined with Lavoltidine.	Investigational
Ledipasvir	The serum concentration of Ledipasvir can be decreased when it is combined with Nelfinavir.	Approved
Ledipasvir	The serum concentration of Ledipasvir can be increased when it is combined with Nelfinavir.	Approved
Lenvatinib	The metabolism of Lenvatinib can be decreased when combined with Nelfinavir.	Approved, Investigational
Lercanidipine	The serum concentration of Lercanidipine can be increased when it is combined with Nelfinavir.	Approved, Investigational
Letrozole	The metabolism of Letrozole can be decreased when combined with Nelfinavir.	Approved, Investigational
Leuprolide	Nelfinavir may increase the QTc-prolonging activities of Leuprolide.	Approved, Investigational
Levetiracetam	The metabolism of Levetiracetam can be decreased when combined with Nelfinavir.	Approved, Investigational
Levobupivacaine	The serum concentration of Levobupivacaine can be increased when it is combined with Nelfinavir.	Approved, Investigational
Levocetirizine	The metabolism of Levocetirizine can be decreased when combined with Nelfinavir.	Approved
Levofloxacin	Nelfinavir may increase the QTc-prolonging activities of Levofloxacin.	Approved, Investigational
Levomethadyl Acetate	The metabolism of Levomethadyl Acetate can be decreased when combined with Nelfinavir.	Approved, Investigational
Levomilnacipran	The serum concentration of Levomilnacipran can be increased when it is combined with Nelfinavir.	Approved, Investigational
Levonorgestrel	The serum concentration of Levonorgestrel can be decreased when it is combined with Nelfinavir.	Approved, Investigational
Levothyroxine	The metabolism of Levothyroxine can be decreased when combined with Nelfinavir.	Approved
Lidocaine	The metabolism of Lidocaine can be decreased when combined with Nelfinavir.	Approved, Vet Approved
Lidoflazine	The metabolism of Lidoflazine can be decreased when combined with Nelfinavir.	Experimental
Linagliptin	The serum concentration of Linagliptin can be decreased when it is combined with Nelfinavir.	Approved
Liraglutide	The therapeutic efficacy of Liraglutide can be decreased when used in combination with Nelfinavir.	Approved
Lisuride	The risk or severity of adverse effects can be increased when Lisuride is combined with Nelfinavir.	Approved, Investigational
Lobeglitazone	The metabolism of Nelfinavir can be decreased when combined with Lobeglitazone.	Approved, Investigational
Lofepramine	The serum concentration of Lofepramine can be increased when it is combined with Nelfinavir.	Experimental
Lofexidine	The metabolism of Lofexidine can be decreased when combined with Nelfinavir.	Approved, Investigational
Lomerizine	The metabolism of Lomerizine can be decreased when combined with Nelfinavir.	Experimental
Lomitapide	The serum concentration of Lomitapide can be increased when it is combined with Nelfinavir.	Approved, Investigational
Loperamide	The metabolism of Loperamide can be decreased when combined with Nelfinavir.	Approved
Lopinavir	The serum concentration of Lopinavir can be decreased when it is combined with Nelfinavir.	Approved
Loratadine	The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Loratadine.	Approved, Investigational
Lorcaserin	The metabolism of Lorcaserin can be decreased when combined with Nelfinavir.	Approved
Lorpiprazole	The serum concentration of Nelfinavir can be increased when it is combined with Lorpiprazole.	Approved
Losartan	The serum concentration of Losartan can be decreased when it is combined with Nelfinavir.	Approved
Loteprednol	The serum concentration of Loteprednol can be increased when it is combined with Nelfinavir.	Approved
Lovastatin	The serum concentration of Lovastatin can be increased when it is combined with Nelfinavir.	Approved, Investigational
Luliconazole	The serum concentration of Nelfinavir can be increased when it is combined with Luliconazole.	Approved
Lumacaftor	The serum concentration of Nelfinavir can be decreased when it is combined with Lumacaftor.	Approved
Lumefantrine	The serum concentration of Lumefantrine can be increased when it is combined with Nelfinavir.	Approved
Lurasidone	The serum concentration of Lurasidone can be increased when it is combined with Nelfinavir.	Approved, Investigational
Lynestrenol	The serum concentration of Lynestrenol can be decreased when it is combined with Nelfinavir.	Approved, Investigational
Lysergic Acid Diethylamide	The risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Nelfinavir.	Illicit, Investigational, Withdrawn
Macimorelin	The metabolism of Macimorelin can be decreased when combined with Nelfinavir.	Approved, Investigational
Macitentan	The serum concentration of Macitentan can be increased when it is combined with Nelfinavir.	Approved
Magnesium sulfate	The metabolism of Magnesium sulfate can be decreased when combined with Nelfinavir.	Approved, Investigational, Vet Approved
Manidipine	The metabolism of Manidipine can be decreased when combined with Nelfinavir.	Approved, Investigational
Maraviroc	The serum concentration of Maraviroc can be increased when it is combined with Nelfinavir.	Approved, Investigational
ME-609	The serum concentration of ME-609 can be increased when it is combined with Nelfinavir.	Investigational
Mebendazole	The metabolism of Mebendazole can be decreased when combined with Nelfinavir.	Approved, Vet Approved
Medical Cannabis	The metabolism of Medical Cannabis can be decreased when combined with Nelfinavir.	Experimental, Investigational
Medroxyprogesterone acetate	The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Nelfinavir.	Approved, Investigational
Medrysone	The serum concentration of Medrysone can be increased when it is combined with Nelfinavir.	Approved
Mefloquine	The metabolism of Mefloquine can be decreased when combined with Nelfinavir.	Approved, Investigational
Megestrol acetate	The serum concentration of Megestrol acetate can be decreased when it is combined with Nelfinavir.	Approved, Investigational, Vet Approved
Melengestrol	The serum concentration of Melengestrol can be increased when it is combined with Nelfinavir.	Vet Approved
Melitracen	The serum concentration of Melitracen can be increased when it is combined with Nelfinavir.	Experimental, Investigational
Meloxicam	The metabolism of Meloxicam can be decreased when combined with Nelfinavir.	Approved, Vet Approved
Menthol	The metabolism of Menthol can be decreased when combined with Nelfinavir.	Approved
Mepyramine	The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Mepyramine.	Approved, Vet Approved
Mestranol	The serum concentration of Mestranol can be decreased when it is combined with Nelfinavir.	Approved
Metergoline	The risk or severity of adverse effects can be increased when Metergoline is combined with Nelfinavir.	Experimental
Metformin	The therapeutic efficacy of Metformin can be decreased when used in combination with Nelfinavir.	Approved
Methadone	The serum concentration of Methadone can be decreased when it is combined with Nelfinavir.	Approved
Methantheline	The serum concentration of Nelfinavir can be decreased when it is combined with Methantheline.	Approved, Investigational
Methaqualone	The metabolism of Methaqualone can be decreased when combined with Nelfinavir.	Illicit, Withdrawn
Methoxsalen	The metabolism of Methoxsalen can be decreased when combined with Nelfinavir.	Approved
Methoxyflurane	The metabolism of Methoxyflurane can be decreased when combined with Nelfinavir.	Approved, Investigational, Vet Approved
Methylergometrine	The risk or severity of adverse effects can be increased when Methylergometrine is combined with Nelfinavir.	Approved
Methylprednisolone	The serum concentration of Methylprednisolone can be increased when it is combined with Nelfinavir.	Approved, Vet Approved
Methyltestosterone	The metabolism of Methyltestosterone can be decreased when combined with Nelfinavir.	Approved
Methysergide	The risk or severity of adverse effects can be increased when Methysergide is combined with Nelfinavir.	Approved
Metiamide	The serum concentration of Nelfinavir can be decreased when it is combined with Metiamide.	Experimental
Metronidazole	The metabolism of Metronidazole can be decreased when combined with Nelfinavir.	Approved
Mevastatin	The serum concentration of Mevastatin can be increased when it is combined with Nelfinavir.	Experimental
Mexiletine	The metabolism of Mexiletine can be decreased when combined with Nelfinavir.	Approved, Investigational
Mianserin	The metabolism of Mianserin can be decreased when combined with Nelfinavir.	Approved, Investigational
Mibefradil	The metabolism of Mibefradil can be decreased when combined with Nelfinavir.	Investigational, Withdrawn
Miconazole	The metabolism of Miconazole can be decreased when combined with Nelfinavir.	Approved, Investigational, Vet Approved
Midazolam	The serum concentration of Midazolam can be increased when it is combined with Nelfinavir.	Approved, Illicit
Midecamycin	The metabolism of Midecamycin can be decreased when combined with Nelfinavir.	Approved
Midostaurin	The metabolism of Midostaurin can be decreased when combined with Nelfinavir.	Approved, Investigational
Mifepristone	The serum concentration of Nelfinavir can be increased when it is combined with Mifepristone.	Approved, Investigational
Miglitol	The therapeutic efficacy of Miglitol can be decreased when used in combination with Nelfinavir.	Approved
Miglustat	The therapeutic efficacy of Miglustat can be decreased when used in combination with Nelfinavir.	Approved
Mirabegron	The metabolism of Mirabegron can be decreased when combined with Nelfinavir.	Approved
Mirtazapine	The metabolism of Mirtazapine can be decreased when combined with Nelfinavir.	Approved
Mitiglinide	The therapeutic efficacy of Mitiglinide can be decreased when used in combination with Nelfinavir.	Approved, Investigational
Mitotane	The serum concentration of Nelfinavir can be decreased when it is combined with Mitotane.	Approved
Modafinil	The metabolism of Modafinil can be decreased when combined with Nelfinavir.	Approved, Investigational
Mometasone	The serum concentration of Mometasone can be increased when it is combined with Nelfinavir.	Approved, Vet Approved
Montelukast	The metabolism of Montelukast can be decreased when combined with Nelfinavir.	Approved
Morphine	The metabolism of Morphine can be decreased when combined with Nelfinavir.	Approved, Investigational
Moxifloxacin	The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Moxifloxacin.	Approved, Investigational
Mycophenolate mofetil	The metabolism of Mycophenolate mofetil can be decreased when combined with Nelfinavir.	Approved, Investigational
Nabiximols	The metabolism of Nabiximols can be decreased when combined with Nelfinavir.	Approved, Investigational
Naftopidil	The metabolism of Naftopidil can be decreased when combined with Nelfinavir.	Investigational
Naloxegol	The serum concentration of Naloxegol can be increased when it is combined with Nelfinavir.	Approved
Naloxone	The metabolism of Naloxone can be decreased when combined with Nelfinavir.	Approved, Vet Approved
Naproxen	The serum concentration of Naproxen can be decreased when it is combined with Nelfinavir.	Approved, Vet Approved
Nateglinide	The metabolism of Nateglinide can be decreased when combined with Nelfinavir.	Approved, Investigational
NCX 1022	The serum concentration of NCX 1022 can be increased when it is combined with Nelfinavir.	Investigational
Nefazodone	The serum concentration of Nefazodone can be increased when it is combined with Nelfinavir.	Approved, Withdrawn
Neratinib	The metabolism of Neratinib can be decreased when combined with Nelfinavir.	Approved, Investigational
Netupitant	The serum concentration of Nelfinavir can be increased when it is combined with Netupitant.	Approved, Investigational
Nevirapine	The serum concentration of the active metabolites of Nelfinavir can be reduced when Nelfinavir is used in combination with Nevirapine resulting in a loss in efficacy.	Approved
Nicardipine	The metabolism of Nicardipine can be decreased when combined with Nelfinavir.	Approved, Investigational
Nicergoline	The risk or severity of adverse effects can be increased when Nicergoline is combined with Nelfinavir.	Approved, Investigational
Nicotine	The metabolism of Nicotine can be decreased when combined with Nelfinavir.	Approved
Nifedipine	The metabolism of Nifedipine can be decreased when combined with Nelfinavir.	Approved
Niguldipine	The metabolism of Niguldipine can be decreased when combined with Nelfinavir.	Experimental
Nilotinib	The serum concentration of Nilotinib can be increased when it is combined with Nelfinavir.	Approved, Investigational
Niludipine	The metabolism of Niludipine can be decreased when combined with Nelfinavir.	Experimental
Nilvadipine	The metabolism of Nilvadipine can be decreased when combined with Nelfinavir.	Approved, Investigational
Nimesulide	The metabolism of Nimesulide can be decreased when combined with Nelfinavir.	Approved, Investigational, Withdrawn
Nimodipine	The serum concentration of Nimodipine can be increased when it is combined with Nelfinavir.	Approved, Investigational
Nintedanib	The serum concentration of Nintedanib can be increased when it is combined with Nelfinavir.	Approved
Niperotidine	The serum concentration of Nelfinavir can be decreased when it is combined with Niperotidine.	Experimental, Investigational
Nisoldipine	The serum concentration of Nisoldipine can be increased when it is combined with Nelfinavir.	Approved
Nitrazepam	The metabolism of Nitrazepam can be decreased when combined with Nelfinavir.	Approved
Nitrendipine	The metabolism of Nitrendipine can be decreased when combined with Nelfinavir.	Approved, Investigational
Nizatidine	The serum concentration of Nelfinavir can be decreased when it is combined with Nizatidine.	Approved
Nomegestrol acetate	The serum concentration of Nomegestrol acetate can be decreased when it is combined with Nelfinavir.	Approved, Investigational
Norelgestromin	The serum concentration of Norelgestromin can be decreased when it is combined with Nelfinavir.	Approved, Investigational
Norethisterone	The serum concentration of Norethisterone can be decreased when it is combined with Nelfinavir.	Approved
Norethynodrel	The serum concentration of Norethynodrel can be decreased when it is combined with Nelfinavir.	Approved
Norgestimate	The serum concentration of Norgestimate can be decreased when it is combined with Nelfinavir.	Approved, Investigational
Norgestrel	The serum concentration of Norgestrel can be decreased when it is combined with Nelfinavir.	Approved
Norgestrienone	The serum concentration of Norgestrienone can be decreased when it is combined with Nelfinavir.	Experimental
Nortriptyline	The metabolism of Nortriptyline can be decreased when combined with Nelfinavir.	Approved
Nylidrin	The metabolism of Nylidrin can be decreased when combined with Nelfinavir.	Approved
Odanacatib	The metabolism of Odanacatib can be decreased when combined with Nelfinavir.	Investigational
Ofloxacin	Nelfinavir may increase the QTc-prolonging activities of Ofloxacin.	Approved
Olanzapine	The serum concentration of Nelfinavir can be decreased when it is combined with Olanzapine.	Approved, Investigational
Olaparib	The serum concentration of Olaparib can be increased when it is combined with Nelfinavir.	Approved
Oleoyl-estrone	The serum concentration of Oleoyl-estrone can be increased when it is combined with Nelfinavir.	Investigational
Olopatadine	The metabolism of Olopatadine can be decreased when combined with Nelfinavir.	Approved
Omeprazole	The serum concentration of Nelfinavir can be decreased when it is combined with Omeprazole.	Approved, Investigational, Vet Approved
Ondansetron	The metabolism of Ondansetron can be decreased when combined with Nelfinavir.	Approved
Opipramol	The serum concentration of Opipramol can be increased when it is combined with Nelfinavir.	Investigational
Opium	The metabolism of Opium can be decreased when combined with Nelfinavir.	Approved, Illicit
Orphenadrine	The metabolism of Orphenadrine can be decreased when combined with Nelfinavir.	Approved
Osimertinib	The serum concentration of Osimertinib can be increased when it is combined with Nelfinavir.	Approved
Ospemifene	The serum concentration of Ospemifene can be increased when it is combined with Nelfinavir.	Approved, Investigational
Otilonium	The metabolism of Otilonium can be decreased when combined with Nelfinavir.	Experimental, Investigational
Oxazepam	The metabolism of Oxazepam can be decreased when combined with Nelfinavir.	Approved
Oxybutynin	The serum concentration of Oxybutynin can be increased when it is combined with Nelfinavir.	Approved, Investigational
Oxycodone	The risk or severity of adverse effects can be increased when Nelfinavir is combined with Oxycodone.	Approved, Illicit, Investigational
Oxymorphone	The metabolism of Oxymorphone can be decreased when combined with Nelfinavir.	Approved, Investigational, Vet Approved
Paclitaxel	The metabolism of Paclitaxel can be decreased when combined with Nelfinavir.	Approved, Vet Approved
Palbociclib	The serum concentration of Palbociclib can be increased when it is combined with Nelfinavir.	Approved, Investigational
Paliperidone	Nelfinavir may increase the QTc-prolonging activities of Paliperidone.	Approved
Palonosetron	The metabolism of Palonosetron can be decreased when combined with Nelfinavir.	Approved, Investigational
Panobinostat	The serum concentration of Panobinostat can be increased when it is combined with Nelfinavir.	Approved, Investigational
Pantoprazole	The serum concentration of the active metabolites of Nelfinavir can be reduced when Nelfinavir is used in combination with Pantoprazole resulting in a loss in efficacy.	Approved
Paramethadione	The metabolism of Paramethadione can be decreased when combined with Nelfinavir.	Approved
Paramethasone	The metabolism of Paramethasone can be decreased when combined with Nelfinavir.	Approved
Parecoxib	The serum concentration of Parecoxib can be increased when it is combined with Nelfinavir.	Approved
Paricalcitol	The serum concentration of Paricalcitol can be increased when it is combined with Nelfinavir.	Approved, Investigational
Paritaprevir	The metabolism of Paritaprevir can be decreased when combined with Nelfinavir.	Approved, Investigational
Paroxetine	The serum concentration of Nelfinavir can be increased when it is combined with Paroxetine.	Approved, Investigational
Pazopanib	The serum concentration of Pazopanib can be increased when it is combined with Nelfinavir.	Approved
Penfluridol	The metabolism of Penfluridol can be decreased when combined with Nelfinavir.	Experimental
Pentamidine	The metabolism of Pentamidine can be decreased when combined with Nelfinavir.	Approved, Investigational
Pentobarbital	The serum concentration of Pentobarbital can be increased when it is combined with Nelfinavir.	Approved, Investigational, Vet Approved
Perampanel	The metabolism of Perampanel can be decreased when combined with Nelfinavir.	Approved
Perflutren	Nelfinavir may increase the QTc-prolonging activities of Perflutren.	Approved
Pergolide	The risk or severity of adverse effects can be increased when Pergolide is combined with Nelfinavir.	Approved, Investigational, Vet Approved, Withdrawn
Perhexiline	The metabolism of Perhexiline can be decreased when combined with Nelfinavir.	Approved, Investigational
Permethrin	The metabolism of Permethrin can be decreased when combined with Nelfinavir.	Approved, Investigational
Perospirone	The metabolism of Perospirone can be decreased when combined with Nelfinavir.	Approved
Perphenazine	The metabolism of Perphenazine can be decreased when combined with Nelfinavir.	Approved
Pethidine	The risk or severity of adverse effects can be increased when Nelfinavir is combined with Pethidine.	Approved
Phenacetin	The metabolism of Phenacetin can be decreased when combined with Nelfinavir.	Withdrawn
Phenformin	The therapeutic efficacy of Phenformin can be decreased when used in combination with Nelfinavir.	Approved, Investigational, Withdrawn
Pheniramine	The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Pheniramine.	Approved
Phenobarbital	The serum concentration of Phenobarbital can be increased when it is combined with Nelfinavir.	Approved, Investigational
Phenoxybenzamine	The metabolism of Phenoxybenzamine can be decreased when combined with Nelfinavir.	Approved
Phenprocoumon	The metabolism of Phenprocoumon can be decreased when combined with Nelfinavir.	Approved, Investigational
Phenytoin	The serum concentration of Phenytoin can be decreased when it is combined with Nelfinavir.	Approved, Vet Approved
Pilocarpine	The metabolism of Pilocarpine can be decreased when combined with Nelfinavir.	Approved, Investigational
Pimecrolimus	The metabolism of Pimecrolimus can be decreased when combined with Nelfinavir.	Approved, Investigational
Pimozide	The serum concentration of Pimozide can be increased when it is combined with Nelfinavir.	Approved
Pinacidil	The metabolism of Pinacidil can be decreased when combined with Nelfinavir.	Approved
Pinaverium	The metabolism of Pinaverium can be decreased when combined with Nelfinavir.	Approved
Pioglitazone	The metabolism of Pioglitazone can be decreased when combined with Nelfinavir.	Approved, Investigational
Piperaquine	The metabolism of Piperaquine can be decreased when combined with Nelfinavir.	Approved, Investigational
Pipotiazine	The metabolism of Pipotiazine can be decreased when combined with Nelfinavir.	Approved, Investigational
Pitavastatin	The serum concentration of Pitavastatin can be increased when it is combined with Nelfinavir.	Approved
Pitolisant	The serum concentration of Pitolisant can be increased when it is combined with Nelfinavir.	Approved, Investigational
Podofilox	The metabolism of Podofilox can be decreased when combined with Nelfinavir.	Approved
Pomalidomide	The metabolism of Pomalidomide can be decreased when combined with Nelfinavir.	Approved
Ponatinib	The serum concentration of Ponatinib can be increased when it is combined with Nelfinavir.	Approved, Investigational
Posaconazole	The metabolism of Posaconazole can be decreased when combined with Nelfinavir.	Approved, Investigational, Vet Approved
Pramlintide	The therapeutic efficacy of Pramlintide can be decreased when used in combination with Nelfinavir.	Approved, Investigational
Pranlukast	The serum concentration of Pranlukast can be increased when it is combined with Nelfinavir.	Approved, Investigational
Prasterone	The metabolism of Prasterone can be decreased when combined with Nelfinavir.	Approved, Investigational, Nutraceutical
Prasterone sulfate	The serum concentration of Prasterone sulfate can be increased when it is combined with Nelfinavir.	Investigational
Prasugrel	The serum concentration of the active metabolites of Prasugrel can be reduced when Prasugrel is used in combination with Nelfinavir resulting in a loss in efficacy.	Approved
Pravastatin	The serum concentration of Pravastatin can be decreased when it is combined with Nelfinavir.	Approved
Prazepam	The metabolism of Prazepam can be decreased when combined with Nelfinavir.	Approved, Illicit
Praziquantel	The metabolism of Praziquantel can be decreased when combined with Nelfinavir.	Approved, Investigational, Vet Approved
Prednicarbate	The serum concentration of Prednicarbate can be increased when it is combined with Nelfinavir.	Approved, Investigational
Prednisolone	The serum concentration of Prednisolone can be increased when it is combined with Nelfinavir.	Approved, Vet Approved
Prednisone	The serum concentration of Prednisone can be increased when it is combined with Nelfinavir.	Approved, Vet Approved
Pregabalin	The metabolism of Pregabalin can be decreased when combined with Nelfinavir.	Approved, Illicit, Investigational
Pregnenolone	The serum concentration of Pregnenolone can be increased when it is combined with Nelfinavir.	Approved, Experimental, Investigational
Prenylamine	The metabolism of Prenylamine can be decreased when combined with Nelfinavir.	Withdrawn
Primaquine	The metabolism of Primaquine can be decreased when combined with Nelfinavir.	Approved
Primidone	The serum concentration of Primidone can be increased when it is combined with Nelfinavir.	Approved, Vet Approved
Procainamide	Nelfinavir may increase the QTc-prolonging activities of Procainamide.	Approved
Prochlorperazine	The metabolism of Prochlorperazine can be decreased when combined with Nelfinavir.	Approved, Vet Approved
Progesterone	The metabolism of Progesterone can be decreased when combined with Nelfinavir.	Approved, Vet Approved
Proguanil	The metabolism of Proguanil can be decreased when combined with Nelfinavir.	Approved
Promazine	The metabolism of Promazine can be decreased when combined with Nelfinavir.	Approved, Vet Approved
Promethazine	The serum concentration of Nelfinavir can be increased when it is combined with Promethazine.	Approved, Investigational
Propafenone	The serum concentration of Propafenone can be increased when it is combined with Nelfinavir.	Approved
Propiverine	The metabolism of Propiverine can be decreased when combined with Nelfinavir.	Approved, Investigational
Propofol	The metabolism of Propofol can be decreased when combined with Nelfinavir.	Approved, Investigational, Vet Approved
Propranolol	The metabolism of Propranolol can be decreased when combined with Nelfinavir.	Approved, Investigational
Protriptyline	The serum concentration of Protriptyline can be increased when it is combined with Nelfinavir.	Approved
Prucalopride	The serum concentration of Prucalopride can be increased when it is combined with Nelfinavir.	Approved
Pyrazinamide	The metabolism of Pyrazinamide can be decreased when combined with Nelfinavir.	Approved, Investigational
Quazepam	The metabolism of Quazepam can be decreased when combined with Nelfinavir.	Approved, Illicit
Quetiapine	The serum concentration of Quetiapine can be increased when it is combined with Nelfinavir.	Approved
Quinacrine	The metabolism of Quinacrine can be decreased when combined with Nelfinavir.	Approved, Investigational
Quingestanol	The serum concentration of Quingestanol can be decreased when it is combined with Nelfinavir.	Experimental
Quinidine	The serum concentration of Quinidine can be increased when it is combined with Nelfinavir.	Approved, Investigational
Quinine	The metabolism of Quinine can be decreased when combined with Nelfinavir.	Approved
Rabeprazole	The serum concentration of the active metabolites of Nelfinavir can be reduced when Nelfinavir is used in combination with Rabeprazole resulting in a loss in efficacy.	Approved, Investigational
Raloxifene	The metabolism of Raloxifene can be decreased when combined with Nelfinavir.	Approved, Investigational
Ramelteon	The serum concentration of Ramelteon can be increased when it is combined with Nelfinavir.	Approved, Investigational
Ranitidine	Ranitidine can cause a decrease in the absorption of Nelfinavir resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Ranolazine	The serum concentration of Ranolazine can be increased when it is combined with Nelfinavir.	Approved, Investigational
Reboxetine	The metabolism of Reboxetine can be decreased when combined with Nelfinavir.	Approved, Investigational
Regorafenib	The metabolism of Regorafenib can be decreased when combined with Nelfinavir.	Approved
Repaglinide	The serum concentration of Repaglinide can be increased when it is combined with Nelfinavir.	Approved, Investigational
Retapamulin	The serum concentration of Retapamulin can be increased when it is combined with Nelfinavir.	Approved
Ribociclib	The serum concentration of Ribociclib can be increased when it is combined with Nelfinavir.	Approved, Investigational
Rifabutin	The serum concentration of the active metabolites of Rifabutin can be increased when Rifabutin is used in combination with Nelfinavir.	Approved, Investigational
Rifampicin	The serum concentration of Nelfinavir can be decreased when it is combined with Rifampicin.	Approved
Rifapentine	The serum concentration of Rifapentine can be increased when it is combined with Nelfinavir.	Approved, Investigational
Rifaximin	The serum concentration of Rifaximin can be increased when it is combined with Nelfinavir.	Approved, Investigational
Rilpivirine	The serum concentration of Rilpivirine can be increased when it is combined with Nelfinavir.	Approved
Rimexolone	The serum concentration of Rimexolone can be increased when it is combined with Nelfinavir.	Approved
Rimonabant	The metabolism of Rimonabant can be decreased when combined with Nelfinavir.	Approved, Investigational
Riociguat	The serum concentration of Riociguat can be increased when it is combined with Nelfinavir.	Approved
Risperidone	The metabolism of Risperidone can be decreased when combined with Nelfinavir.	Approved, Investigational
Ritonavir	The metabolism of Ritonavir can be decreased when combined with Nelfinavir.	Approved, Investigational
Rivaroxaban	The metabolism of Rivaroxaban can be decreased when combined with Nelfinavir.	Approved
Rofecoxib	The metabolism of Rofecoxib can be decreased when combined with Nelfinavir.	Approved, Investigational, Withdrawn
Rolapitant	The metabolism of Rolapitant can be decreased when combined with Nelfinavir.	Approved, Investigational
Romidepsin	The serum concentration of Romidepsin can be increased when it is combined with Nelfinavir.	Approved, Investigational
Ropinirole	The metabolism of Ropinirole can be decreased when combined with Nelfinavir.	Approved, Investigational
Ropivacaine	The metabolism of Ropivacaine can be decreased when combined with Nelfinavir.	Approved
Rosiglitazone	The metabolism of Rosiglitazone can be decreased when combined with Nelfinavir.	Approved, Investigational
Rosuvastatin	The metabolism of Rosuvastatin can be decreased when combined with Nelfinavir.	Approved
Rotigotine	The metabolism of Rotigotine can be decreased when combined with Nelfinavir.	Approved
Roxatidine acetate	The serum concentration of Nelfinavir can be decreased when it is combined with Roxatidine acetate.	Approved, Investigational
Roxithromycin	The metabolism of Roxithromycin can be decreased when combined with Nelfinavir.	Approved, Investigational, Withdrawn
Rucaparib	The metabolism of Rucaparib can be decreased when combined with Nelfinavir.	Approved, Investigational
Rupatadine	The metabolism of Rupatadine can be decreased when combined with Nelfinavir.	Approved
Ruxolitinib	The serum concentration of Ruxolitinib can be increased when it is combined with Nelfinavir.	Approved
Safinamide	The metabolism of Safinamide can be decreased when combined with Nelfinavir.	Approved, Investigational
Salbutamol	The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Salbutamol.	Approved, Vet Approved
Salmeterol	The serum concentration of Salmeterol can be increased when it is combined with Nelfinavir.	Approved
Saquinavir	The metabolism of Saquinavir can be decreased when combined with Nelfinavir.	Approved, Investigational
Sarilumab	The therapeutic efficacy of Nelfinavir can be decreased when used in combination with Sarilumab.	Approved, Investigational
Saxagliptin	The serum concentration of Saxagliptin can be increased when it is combined with Nelfinavir.	Approved
Selegiline	The metabolism of Selegiline can be decreased when combined with Nelfinavir.	Approved, Investigational, Vet Approved
Seletracetam	The metabolism of Seletracetam can be decreased when combined with Nelfinavir.	Investigational
Selexipag	The metabolism of Selexipag can be decreased when combined with Nelfinavir.	Approved
Seratrodast	The metabolism of Seratrodast can be decreased when combined with Nelfinavir.	Approved
Sertindole	The metabolism of Sertindole can be decreased when combined with Nelfinavir.	Approved, Investigational, Withdrawn
Sertraline	The metabolism of Sertraline can be decreased when combined with Nelfinavir.	Approved
Sevoflurane	The metabolism of Sevoflurane can be decreased when combined with Nelfinavir.	Approved, Vet Approved
Sibutramine	The metabolism of Sibutramine can be decreased when combined with Nelfinavir.	Approved, Illicit, Investigational, Withdrawn
Sildenafil	The serum concentration of Sildenafil can be increased when it is combined with Nelfinavir.	Approved, Investigational
Silodosin	The serum concentration of Silodosin can be increased when it is combined with Nelfinavir.	Approved
Siltuximab	The serum concentration of Nelfinavir can be decreased when it is combined with Siltuximab.	Approved, Investigational
Simeprevir	The serum concentration of Simeprevir can be increased when it is combined with Nelfinavir.	Approved
Simvastatin	The serum concentration of Simvastatin can be increased when it is combined with Nelfinavir.	Approved
Sirolimus	The serum concentration of Sirolimus can be increased when it is combined with Nelfinavir.	Approved, Investigational
Sitagliptin	The metabolism of Sitagliptin can be decreased when combined with Nelfinavir.	Approved, Investigational
Sofosbuvir	The serum concentration of Sofosbuvir can be decreased when it is combined with Nelfinavir.	Approved
Solifenacin	The metabolism of Solifenacin can be decreased when combined with Nelfinavir.	Approved
Sonidegib	The serum concentration of Sonidegib can be increased when it is combined with Nelfinavir.	Approved, Investigational
Sorafenib	The serum concentration of Sorafenib can be increased when it is combined with Nelfinavir.	Approved, Investigational
Sotagliflozin	The therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Nelfinavir.	Investigational
Sotalol	Nelfinavir may increase the QTc-prolonging activities of Sotalol.	Approved
Spiramycin	The metabolism of Spiramycin can be decreased when combined with Nelfinavir.	Approved
St. John's Wort	The metabolism of Nelfinavir can be increased when combined with St. John's Wort.	Approved, Investigational, Nutraceutical
Stiripentol	The serum concentration of Nelfinavir can be increased when it is combined with Stiripentol.	Approved
Sufentanil	The metabolism of Sufentanil can be decreased when combined with Nelfinavir.	Approved, Investigational
Sulfadiazine	The metabolism of Sulfadiazine can be decreased when combined with Nelfinavir.	Approved, Investigational, Vet Approved
Sulfamethoxazole	The metabolism of Sulfamethoxazole can be decreased when combined with Nelfinavir.	Approved
Sulfasalazine	The serum concentration of Sulfasalazine can be increased when it is combined with Nelfinavir.	Approved
Sulfinpyrazone	The metabolism of Sulfinpyrazone can be decreased when combined with Nelfinavir.	Approved
Sulfisoxazole	The metabolism of Nelfinavir can be decreased when combined with Sulfisoxazole.	Approved, Vet Approved
Sulodexide	The therapeutic efficacy of Sulodexide can be decreased when used in combination with Nelfinavir.	Approved, Investigational
Sumatriptan	The serum concentration of Sumatriptan can be increased when it is combined with Nelfinavir.	Approved, Investigational
Sunitinib	The metabolism of Sunitinib can be decreased when combined with Nelfinavir.	Approved, Investigational
Suvorexant	The serum concentration of Suvorexant can be increased when it is combined with Nelfinavir.	Approved, Investigational
Synthetic Conjugated Estrogens, A	The metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Nelfinavir.	Approved
Synthetic Conjugated Estrogens, B	The metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Nelfinavir.	Approved
Tacrolimus	The metabolism of Tacrolimus can be decreased when combined with Nelfinavir.	Approved, Investigational
Tadalafil	The serum concentration of Tadalafil can be increased when it is combined with Nelfinavir.	Approved, Investigational
Tamoxifen	The metabolism of Tamoxifen can be decreased when combined with Nelfinavir.	Approved
Tamsulosin	The serum concentration of Tamsulosin can be increased when it is combined with Nelfinavir.	Approved, Investigational
Tapentadol	The metabolism of Tapentadol can be decreased when combined with Nelfinavir.	Approved
Tasimelteon	The serum concentration of Tasimelteon can be increased when it is combined with Nelfinavir.	Approved, Investigational
Tasosartan	The metabolism of Tasosartan can be decreased when combined with Nelfinavir.	Approved
Taurochenodeoxycholic acid	The metabolism of Taurochenodeoxycholic acid can be decreased when combined with Nelfinavir.	Experimental
Telaprevir	The metabolism of Telaprevir can be decreased when combined with Nelfinavir.	Approved, Withdrawn
Telavancin	Nelfinavir may increase the QTc-prolonging activities of Telavancin.	Approved
Telithromycin	The metabolism of Telithromycin can be decreased when combined with Nelfinavir.	Approved
Temazepam	The metabolism of Temazepam can be decreased when combined with Nelfinavir.	Approved, Investigational
Temsirolimus	The risk or severity of adverse effects can be increased when Nelfinavir is combined with Temsirolimus.	Approved
Teniposide	The metabolism of Teniposide can be decreased when combined with Nelfinavir.	Approved
Terbinafine	The metabolism of Terbinafine can be decreased when combined with Nelfinavir.	Approved, Investigational, Vet Approved
Terfenadine	The serum concentration of Terfenadine can be increased when it is combined with Nelfinavir.	Approved, Withdrawn
Terguride	The risk or severity of adverse effects can be increased when Terguride is combined with Nelfinavir.	Experimental
Terodiline	The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Terodiline.	Experimental
Tesmilifene	The metabolism of Tesmilifene can be decreased when combined with Nelfinavir.	Investigational
Testosterone	The metabolism of Testosterone can be decreased when combined with Nelfinavir.	Approved, Investigational
Testosterone cypionate	The metabolism of Testosterone cypionate can be decreased when combined with Nelfinavir.	Approved
Testosterone enanthate	The metabolism of Testosterone enanthate can be decreased when combined with Nelfinavir.	Approved
Testosterone propionate	The metabolism of Testosterone propionate can be decreased when combined with Nelfinavir.	Approved, Investigational, Vet Approved, Withdrawn
Testosterone undecanoate	The metabolism of Testosterone undecanoate can be decreased when combined with Nelfinavir.	Approved, Investigational
Tetrabenazine	Nelfinavir may increase the QTc-prolonging activities of Tetrabenazine.	Approved, Investigational
Tetracycline	The metabolism of Tetracycline can be decreased when combined with Nelfinavir.	Approved, Vet Approved
Tetrahydropalmatine	The metabolism of Tetrahydropalmatine can be decreased when combined with Nelfinavir.	Investigational
Tetrandrine	The metabolism of Tetrandrine can be decreased when combined with Nelfinavir.	Experimental
Tezacaftor	The metabolism of Tezacaftor can be decreased when combined with Nelfinavir.	Approved, Investigational
Theophylline	The metabolism of Theophylline can be decreased when combined with Nelfinavir.	Approved
Thioridazine	The serum concentration of Thioridazine can be increased when it is combined with Nelfinavir.	Approved, Withdrawn
Thiotepa	The metabolism of Thiotepa can be decreased when combined with Nelfinavir.	Approved, Investigational
Tiagabine	The metabolism of Tiagabine can be decreased when combined with Nelfinavir.	Approved, Investigational
Tianeptine	The serum concentration of Tianeptine can be increased when it is combined with Nelfinavir.	Approved, Investigational
Ticagrelor	The serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Nelfinavir resulting in a loss in efficacy.	Approved
Ticlopidine	The metabolism of Ticlopidine can be decreased when combined with Nelfinavir.	Approved
Tinidazole	The metabolism of Tinidazole can be decreased when combined with Nelfinavir.	Approved, Investigational
Tiotropium	The metabolism of Tiotropium can be decreased when combined with Nelfinavir.	Approved
Tipranavir	The serum concentration of Nelfinavir can be decreased when it is combined with Tipranavir.	Approved, Investigational
Tixocortol	The serum concentration of Tixocortol can be increased when it is combined with Nelfinavir.	Approved, Withdrawn
Tizanidine	The serum concentration of Tizanidine can be increased when it is combined with Nelfinavir.	Approved, Investigational
Tocilizumab	The serum concentration of Nelfinavir can be decreased when it is combined with Tocilizumab.	Approved
Tocofersolan	The metabolism of Tocofersolan can be decreased when combined with Nelfinavir.	Approved
Tocopherol	The metabolism of Tocopherol can be decreased when combined with Nelfinavir.	Approved, Investigational
Tofacitinib	The serum concentration of Tofacitinib can be increased when it is combined with Nelfinavir.	Approved, Investigational
Tolazamide	The therapeutic efficacy of Tolazamide can be decreased when used in combination with Nelfinavir.	Approved, Investigational
Tolfenamic Acid	The metabolism of Tolfenamic Acid can be decreased when combined with Nelfinavir.	Approved, Investigational
Tolterodine	The serum concentration of Tolterodine can be increased when it is combined with Nelfinavir.	Approved, Investigational
Tolvaptan	The serum concentration of Tolvaptan can be increased when it is combined with Nelfinavir.	Approved
Topiramate	The serum concentration of Topiramate can be increased when it is combined with Nelfinavir.	Approved
Topotecan	The serum concentration of Topotecan can be increased when it is combined with Nelfinavir.	Approved, Investigational
Toremifene	The risk or severity of adverse effects can be increased when Nelfinavir is combined with Toremifene.	Approved, Investigational
Trabectedin	The serum concentration of Trabectedin can be increased when it is combined with Nelfinavir.	Approved, Investigational
Tramadol	The serum concentration of Tramadol can be increased when it is combined with Nelfinavir.	Approved, Investigational
Tranilast	The metabolism of Tranilast can be decreased when combined with Nelfinavir.	Approved, Investigational
Tranylcypromine	The metabolism of Nelfinavir can be decreased when combined with Tranylcypromine.	Approved, Investigational
Trastuzumab emtansine	The serum concentration of the active metabolites of Trastuzumab emtansine can be increased when Trastuzumab emtansine is used in combination with Nelfinavir.	Approved, Investigational
Trazodone	The serum concentration of Trazodone can be increased when it is combined with Nelfinavir.	Approved, Investigational
Tretinoin	The metabolism of Tretinoin can be decreased when combined with Nelfinavir.	Approved, Investigational, Nutraceutical
Triamcinolone	The metabolism of Triamcinolone can be decreased when combined with Nelfinavir.	Approved, Vet Approved
Triazolam	The serum concentration of Triazolam can be increased when it is combined with Nelfinavir.	Approved, Investigational
Trimebutine	The metabolism of Trimebutine can be decreased when combined with Nelfinavir.	Approved
Trimethadione	The metabolism of Trimethadione can be decreased when combined with Nelfinavir.	Approved
Trimethoprim	The metabolism of Trimethoprim can be decreased when combined with Nelfinavir.	Approved, Vet Approved
Trimipramine	The metabolism of Trimipramine can be decreased when combined with Nelfinavir.	Approved
Troglitazone	The metabolism of Troglitazone can be decreased when combined with Nelfinavir.	Investigational, Withdrawn
Troleandomycin	The metabolism of Troleandomycin can be decreased when combined with Nelfinavir.	Approved
Udenafil	The metabolism of Udenafil can be decreased when combined with Nelfinavir.	Approved, Investigational
Ulipristal	The serum concentration of Ulipristal can be increased when it is combined with Nelfinavir.	Approved
Ulobetasol	The serum concentration of Ulobetasol can be increased when it is combined with Nelfinavir.	Approved
Valbenazine	The metabolism of Valbenazine can be decreased when combined with Nelfinavir.	Approved, Investigational
Valdecoxib	The metabolism of Valdecoxib can be decreased when combined with Nelfinavir.	Approved, Investigational, Withdrawn
Valproic Acid	The serum concentration of Valproic Acid can be decreased when it is combined with Nelfinavir.	Approved, Investigational
Vandetanib	The metabolism of Vandetanib can be decreased when combined with Nelfinavir.	Approved
Vanoxerine	The metabolism of Vanoxerine can be decreased when combined with Nelfinavir.	Investigational
Vardenafil	The serum concentration of Vardenafil can be increased when it is combined with Nelfinavir.	Approved
Velpatasvir	The metabolism of Velpatasvir can be decreased when combined with Nelfinavir.	Approved, Investigational
Vemurafenib	The serum concentration of Vemurafenib can be increased when it is combined with Nelfinavir.	Approved
Venetoclax	The metabolism of Venetoclax can be decreased when combined with Nelfinavir.	Approved, Investigational
Venlafaxine	The metabolism of Venlafaxine can be decreased when combined with Nelfinavir.	Approved
Verapamil	The metabolism of Verapamil can be decreased when combined with Nelfinavir.	Approved
Vicriviroc	The metabolism of Vicriviroc can be decreased when combined with Nelfinavir.	Investigational
Vilanterol	The metabolism of Vilanterol can be decreased when combined with Nelfinavir.	Approved
Vilazodone	The serum concentration of Vilazodone can be increased when it is combined with Nelfinavir.	Approved
Vildagliptin	The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Nelfinavir.	Approved, Investigational
Vinblastine	The metabolism of Vinblastine can be decreased when combined with Nelfinavir.	Approved
Vincristine	The serum concentration of Vincristine can be increased when it is combined with Nelfinavir.	Approved, Investigational
Vincristine	The metabolism of Vincristine can be decreased when combined with Nelfinavir.	Approved, Investigational
Vindesine	The serum concentration of Vindesine can be increased when it is combined with Nelfinavir.	Approved, Investigational
Vinflunine	The metabolism of Vinflunine can be decreased when combined with Nelfinavir.	Approved, Investigational
Vinorelbine	The metabolism of Vinorelbine can be decreased when combined with Nelfinavir.	Approved, Investigational
Vinpocetine	The metabolism of Vinpocetine can be decreased when combined with Nelfinavir.	Investigational
Vismodegib	The metabolism of Vismodegib can be decreased when combined with Nelfinavir.	Approved, Investigational
Voglibose	The therapeutic efficacy of Voglibose can be decreased when used in combination with Nelfinavir.	Approved, Investigational
Vorapaxar	The serum concentration of Vorapaxar can be increased when it is combined with Nelfinavir.	Approved
Voriconazole	The serum concentration of Nelfinavir can be increased when it is combined with Voriconazole.	Approved, Investigational
Vortioxetine	The metabolism of Vortioxetine can be decreased when combined with Nelfinavir.	Approved, Investigational
Voxilaprevir	The metabolism of Voxilaprevir can be decreased when combined with Nelfinavir.	Approved, Investigational
Warfarin	The serum concentration of Warfarin can be decreased when it is combined with Nelfinavir.	Approved
WIN 55212-2	The metabolism of WIN 55212-2 can be decreased when combined with Nelfinavir.	Experimental
Yohimbine	The metabolism of Yohimbine can be decreased when combined with Nelfinavir.	Approved, Investigational, Vet Approved
Zafirlukast	The metabolism of Zafirlukast can be decreased when combined with Nelfinavir.	Approved, Investigational
Zalcitabine	The metabolism of Zalcitabine can be decreased when combined with Nelfinavir.	Approved, Investigational
Zaleplon	The metabolism of Zaleplon can be decreased when combined with Nelfinavir.	Approved, Illicit, Investigational
Ziconotide	The metabolism of Ziconotide can be decreased when combined with Nelfinavir.	Approved
Zidovudine	The serum concentration of Zidovudine can be decreased when it is combined with Nelfinavir.	Approved
Zileuton	The metabolism of Zileuton can be decreased when combined with Nelfinavir.	Approved, Investigational, Withdrawn
Ziprasidone	The metabolism of Ziprasidone can be decreased when combined with Nelfinavir.	Approved
Zolpidem	The metabolism of Zolpidem can be decreased when combined with Nelfinavir.	Approved
Zomepirac	The metabolism of Zomepirac can be decreased when combined with Nelfinavir.	Withdrawn
Zonisamide	The serum concentration of Zonisamide can be decreased when it is combined with Nelfinavir.	Approved, Investigational
Zopiclone	The serum concentration of Zopiclone can be increased when it is combined with Nelfinavir.	Approved
Zotepine	The metabolism of Zotepine can be decreased when combined with Nelfinavir.	Approved, Investigational, Withdrawn
Zucapsaicin	The metabolism of Nelfinavir can be decreased when combined with Zucapsaicin.	Approved, Investigational
Zuclopenthixol	The serum concentration of Zuclopenthixol can be increased when it is combined with Nelfinavir.	Approved, Investigational

Food Interactions

• Food significantly increases absorption (2 to 3 times).
• Take with food.

References

Synthesis Reference

US5461154

General References

1. Kaldor SW, Kalish VJ, Davies JF 2nd, Shetty BV, Fritz JE, Appelt K, Burgess JA, Campanale KM, Chirgadze NY, Clawson DK, Dressman BA, Hatch SD, Khalil DA, Kosa MB, Lubbehusen PP, Muesing MA, Patick AK, Reich SH, Su KS, Tatlock JH: Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. J Med Chem. 1997 Nov 21;40(24):3979-85. [PubMed:9397180]

External Links

Human Metabolome Database

HMDB0014365

KEGG Drug

D08259

KEGG Compound

C07257

PubChem Compound

64143

PubChem Substance

46507719

ChemSpider

57718

BindingDB

518

ChEBI

7496

ChEMBL

CHEMBL584

Therapeutic Targets Database

DAP000705

PharmGKB

PA450606

HET

1UN

RxList

RxList Drug Page

Drugs.com

Drugs.com Drug Page

PDRhealth

PDRhealth Drug Page

Wikipedia

Nelfinavir

ATC Codes

J05AE04 — Nelfinavir

• J05AE — Protease inhibitors
• J05A — DIRECT ACTING ANTIVIRALS
• J05 — ANTIVIRALS FOR SYSTEMIC USE
• J — ANTIINFECTIVES FOR SYSTEMIC USE

AHFS Codes

• 08:18.08.08 — HIV Protease Inhibitors

PDB Entries

1ohr / 2pym / 2pyn / 2q63 / 2q64 / 2qak / 2r5q / 3ekx / 3el0 / 3el5

FDA label

Download (294 KB)

MSDS

Download (56.6 KB)

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
0	Terminated	Treatment	Castleman's Disease / EBV / Kaposi s Sarcoma (KS) / Lymphoma, Hodgkins / Malignant Neoplasm of Nasopharynx / Malignant Neoplasm of Stomach / Non-Hodgkin's Lymphoma (NHL)	1
1	Active Not Recruiting	Not Available	Gliomas	1
1	Active Not Recruiting	Treatment	Adenocarcinoma of the Pancreas / Stage III Pancreatic Cancer	1
1	Active Not Recruiting	Treatment	Brain and Central Nervous System Tumors	1
1	Active Not Recruiting	Treatment	Cancer of the Ovary / Carcinoid tumour of the gastrointestinal tract / Colorectal Cancers / Head and Neck Carcinoma / Islet Cell Tumor / Lung Cancers / Metastatic Cancers / Neuroendocrine Carcinoma of the Skin / Pheochromocytomas / Sarcomas / Unspecified Adult Solid Tumor, Protocol Specific	1
1	Active Not Recruiting	Treatment	Lung Cancer Non-Small Cell Cancer (NSCLC)	1
1	Completed	Treatment	Cancers / Renal Cell Adenocarcinoma	1
1	Completed	Treatment	Cervical Cancers	1
1	Completed	Treatment	Glioblastomas	1
1	Completed	Treatment	HIV Seronegativity / Human Immunodeficiency Virus (HIV) Infections / Lipodystrophies	1
1	Completed	Treatment	Healthy Volunteers	1
1	Completed	Treatment	Human Immunodeficiency Virus (HIV) Infections	12
1	Completed	Treatment	Human Immunodeficiency Virus (HIV) Infections / Pregnancy	1
1	Completed	Treatment	Human Immunodeficiency Virus (HIV) Infections / Tuberculosis	1
1	Completed	Treatment	Immune Response	1
1	Completed	Treatment	Leukemias / Malignant Lymphomas / Mature T-cell and Nk-cell Neoplasms / Multiple Myeloma and Plasma Cell Neoplasm	1
1	Completed	Treatment	Sepsis	1
1	Completed	Treatment	Tumors, Solid	1
1	Recruiting	Treatment	Uterine Cervix Cancer	1
1	Terminated	Prevention	Cardiopulmonary Bypass	1
1	Terminated	Treatment	Neoplasms, Pancreatic	1
1	Withdrawn	Treatment	Malignant Lymphomas / Neoplasms	1
1, 2	Active Not Recruiting	Treatment	Lung Cancers	1
1, 2	Active Not Recruiting	Treatment	Multiple Myeloma (MM)	1
1, 2	Completed	Treatment	Carcinoma, Colorectal / Colorectal Cancers / Colorectal Tumors / Neoplasms, Colorectal	1
1, 2	Recruiting	Treatment	Pancreatic Neoplasms (Locally Advanced Non-metastatic)	1
1, 2	Terminated	Treatment	Adult Liposarcoma / Recurrent Adult Soft Tissue Sarcoma / Stage III Adult Soft Tissue Sarcoma / Stage IV Adult Soft Tissue Sarcoma	1
1, 2	Withdrawn	Treatment	Lung Cancers	1
2	Active Not Recruiting	Treatment	Adenocarcinoma of the Pancreas / Resectable Pancreatic Cancers / Resectable Pancreatic Carcinoma / Stage I Pancreatic Cancer / Stage IA Pancreatic Cancer / Stage IB Pancreatic Cancer / Stage II Pancreatic Cancer / Stage IIA Pancreatic Cancer / Stage IIB Pancreatic Cancer / Stage III Pancreatic Cancer	1
2	Active Not Recruiting	Treatment	Oligometastases	1
2	Completed	Treatment	Carcinoma, Adenoid Cystic / Neoplasms, Head and Neck	1
2	Completed	Treatment	Cytomegalovirus Retinitis / Human Immunodeficiency Virus (HIV) Infections	1
2	Completed	Treatment	Human Immunodeficiency Virus (HIV) Infections	16
2	Completed	Treatment	Human Immunodeficiency Virus (HIV) Infections / Infection, Mycobacterium Avium-Intracellulare	1
2	Completed	Treatment	Human Immunodeficiency Virus (HIV) Infections / Kaposi s Sarcoma (KS)	1
2	Completed	Treatment	Plasma Cell Myeloma	1
2	Completed	Treatment	Sarcomas	1
2	Completed	Treatment	Systemic Lupus Erythematosus (SLE)	1
2	Recruiting	Diagnostic	Stage III, IVa, or IVb Squamous Cell Carcinoma of the Oral Cavity, Oropharynx, Larynx, or Hypopharynx	1
2	Recruiting	Treatment	Cervical Dysplasia	1
2	Recruiting	Treatment	Metastatic Renal Cell Cancer / Recurrent Melanoma / Recurrent Non-Small Cell Lung Carcinoma / Renal Cell Carcinoma Recurrent / Stage IV Cutaneous Melanoma AJCC v6 and v7 / Stage IV Non-Small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer AJCC v7 / Stage IV Renal Cell Cancer / Stage IV Renal Cell Cancer AJCC V7 / Stage IV Skin Melanoma	1
2	Recruiting	Treatment	Recurrent Kaposi's Sarcoma / Skin Kaposi Sarcoma	1
2	Suspended	Treatment	Human Immunodeficiency Virus (HIV) Infections	2
2	Terminated	Treatment	Lung Cancer Non-Small Cell Cancer (NSCLC)	1
2	Unknown Status	Treatment	Human Immunodeficiency Virus (HIV) Infections	1
2	Withdrawn	Treatment	Human Immunodeficiency Virus (HIV) Infections	1
2, 3	Completed	Treatment	Human Immunodeficiency Virus (HIV) Infections	1
3	Completed	Prevention	Disease Transmission, Vertical / Human Immunodeficiency Virus (HIV) Infections / Vertical Human Immunodeficiency Virus Transmission	1
3	Completed	Treatment	AIDS-Associated Nephropathy / Human Immunodeficiency Virus (HIV) Infections	1
3	Completed	Treatment	Human Immunodeficiency Virus (HIV) Infections	9
3	Completed	Treatment	Human Immunodeficiency Virus (HIV) Infections / Pregnancy	1
3	Not Yet Recruiting	Treatment	Carcinoma Cervix, Stage III	1
3	Terminated	Prevention	Diarrhea	1
3	Terminated	Treatment	Human Immunodeficiency Virus (HIV) Infections	1
3	Unknown Status	Treatment	Human Immunodeficiency Virus (HIV) Infections	3
4	Completed	Diagnostic	Cardiovascular Disease (CVD) / HIV-Associated Lipodystrophy Syndrome	1
4	Completed	Diagnostic	Human Immunodeficiency Virus (HIV) Infections / Lipodystrophies	1
4	Completed	Treatment	Healthy Volunteers	2
4	Completed	Treatment	Human Immunodeficiency Virus (HIV) Infections	2
4	Completed	Treatment	Human Immunodeficiency Virus (HIV) Infections / Tuberculosis	1
4	Unknown Status	Treatment	Human Immunodeficiency Virus (HIV) Infections	1
Not Available	Completed	Treatment	Human Immunodeficiency Virus (HIV) Infections	20
Not Available	Completed	Treatment	Human Immunodeficiency Virus (HIV) Infections / Infection, Mycobacterium Avium-Intracellulare	1
Not Available	Terminated	Treatment	Human Immunodeficiency Virus (HIV) Infections	1
Not Available	Unknown Status	Treatment	Human Immunodeficiency Virus (HIV) Infections	1

Pharmacoeconomics

Manufacturers

• Agouron pharmaceuticals inc

Packagers

• Agouron Pharmaceuticals Inc.
• A-S Medication Solutions LLC
• Cardinal Health
• Dept Health Central Pharmacy
• Dispensing Solutions
• Goedecke GmbH
• H.J. Harkins Co. Inc.
• Kaiser Foundation Hospital
• Lake Erie Medical and Surgical Supply
• Patheon Inc.
• PD-Rx Pharmaceuticals Inc.
• Pfizer Inc.
• Physicians Total Care Inc.
• Quality Care
• Remedy Repack
• St Mary's Medical Park Pharmacy
• Watson Pharmaceuticals

Dosage forms

Form	Route	Strength
Powder	Oral	50 mg/g
Tablet	Oral	625 mg
Tablet, film coated	Oral	250 mg/1
Tablet, film coated	Oral	625 mg/1
Tablet	Oral	250 mg
Powder	Oral	50 mg

Prices

Unit description	Cost	Unit
Viracept 625 mg tablet	11.24USD	tablet
Viracept 250 mg tablet	3.46USD	tablet
Viracept 50 mg/gm Powder	0.54USD	gm

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)
US5484926	No	1994-04-07	2014-04-07
CA2173328	No	1999-08-31	2014-10-07

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	349.84 °C	Not Available
water solubility	Slightly soluble	Not Available
logP	6	Not Available

Predicted Properties

Property	Value	Source
Water Solubility	0.00191 mg/mL	ALOGPS
logP	4.61	ALOGPS
logP	4.72	ChemAxon
logS	-5.5	ALOGPS
pKa (Strongest Acidic)	9.32	ChemAxon
pKa (Strongest Basic)	8.18	ChemAxon
Physiological Charge	1	ChemAxon
Hydrogen Acceptor Count	5	ChemAxon
Hydrogen Donor Count	4	ChemAxon
Polar Surface Area	101.9 Å2	ChemAxon
Rotatable Bond Count	10	ChemAxon
Refractivity	162.67 m3·mol-1	ChemAxon
Polarizability	63.8 Å3	ChemAxon
Number of Rings	4	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	No	ChemAxon
Ghose Filter	No	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	Yes	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	0.7472
Blood Brain Barrier	-	0.9659
Caco-2 permeable	-	0.7148
P-glycoprotein substrate	Substrate	0.9332
P-glycoprotein inhibitor I	Inhibitor	0.8121
P-glycoprotein inhibitor II	Inhibitor	0.7572
Renal organic cation transporter	Non-inhibitor	0.8178
CYP450 2C9 substrate	Non-substrate	0.7482
CYP450 2D6 substrate	Substrate	0.8918
CYP450 3A4 substrate	Substrate	0.7408
CYP450 1A2 substrate	Non-inhibitor	0.9085
CYP450 2C9 inhibitor	Non-inhibitor	0.7994
CYP450 2D6 inhibitor	Non-inhibitor	0.8071
CYP450 2C19 inhibitor	Non-inhibitor	0.6335
CYP450 3A4 inhibitor	Inhibitor	0.5465
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.8977
Ames test	Non AMES toxic	0.8008
Carcinogenicity	Non-carcinogens	0.8547
Biodegradation	Not ready biodegradable	1.0
Rat acute toxicity	2.4704 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.9786
hERG inhibition (predictor II)	Inhibitor	0.785

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted GC-MS Spectrum - GC-MS	Predicted GC-MS	Not Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	Not Available

Taxonomy

Description

This compound belongs to the class of organic compounds known as alpha amino acid amides. These are amide derivatives of alpha amino acids.

Kingdom

Organic compounds

Super Class

Organic acids and derivatives

Class

Carboxylic acids and derivatives

Sub Class

Amino acids, peptides, and analogues

Direct Parent

Alpha amino acid amides

Alternative Parents

o-Toluamides / Piperidinecarboxamides / Benzamides / Thiophenol ethers / Ortho cresols / Benzoyl derivatives / 1-hydroxy-2-unsubstituted benzenoids / 1-hydroxy-4-unsubstituted benzenoids / Alkylarylthioethers / Trialkylamines1,2-aminoalcohols / Secondary carboxylic acid amides / Secondary alcohols / Sulfenyl compounds / Azacyclic compounds / Hydrocarbon derivatives / Organic oxides / Organopnictogen compounds / Carbonyl compounds

show 9 more

Substituents

Alpha-amino acid amide / Piperidinecarboxamide / 2-piperidinecarboxamide / Toluamide / Benzamide / O-toluamide / Benzoic acid or derivatives / Thiophenol ether / O-cresol / BenzoylAryl thioether / Phenol / Alkylarylthioether / 1-hydroxy-2-unsubstituted benzenoid / Toluene / 1-hydroxy-4-unsubstituted benzenoid / Benzenoid / Piperidine / Monocyclic benzene moiety / 1,2-aminoalcohol / Carboxamide group / Tertiary aliphatic amine / Secondary alcohol / Secondary carboxylic acid amide / Tertiary amine / Organoheterocyclic compound / Azacycle / Sulfenyl compound / Thioether / Organosulfur compound / Organooxygen compound / Organonitrogen compound / Alcohol / Carbonyl group / Hydrocarbon derivative / Organic oxide / Organopnictogen compound / Organic nitrogen compound / Amine / Organic oxygen compound / Aromatic heteropolycyclic compound

show 31 more

Molecular Framework

Aromatic heteropolycyclic compounds

External Descriptors

tertiary amino compound, secondary alcohol, aryl sulfide, phenols, benzamides, organic heterobicyclic compound (CHEBI:7496)

Drug created on June 13, 2005 07:24 / Updated on August 14, 2018 07:17